Content
Quantexa News
09/16
Headlands Technologies LLC Invests $129,000 in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Headlands Technologies LLC bought a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities &...
Polygon News
09/16
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
Iovance Biotherapeutics is a hot biotech stock with rapid revenue growth, but it may not be profitable for some time due to high manufacturing costs. The company is working on improving its manufactur...
Yahoo Finance News
09/16
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today Alex Carchidi, The Motley Fool Mon, Sep 16, 2024, 6:29 AM 5 min read In This Article: IOVA Iovance Biotherapeutics (NASDAQ: IOVA) is...
Yahoo Finance News
09/16
Iovance Biotherapeutics (NASDAQ:IOVA) delivers shareholders favorable 74% return over 1 year, surging 4.9% in the last week alone
Iovance Biotherapeutics (NASDAQ:IOVA) delivers shareholders favorable 74% return over 1 year, surging 4.9% in the last week alone editorial-team@simplywallst.com (Simply Wall St) Mon, Sep 16, 2024, 2:...
Quantexa News
09/17
Wealthspire Advisors LLC Acquires Shares of 57,000 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Wealthspire Advisors LLC bought a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) in the 2nd quarter, HoldingsChannel reports. The fund bought 57,000 shares of the bio...
Yahoo Finance Community
09/17
Comment
Here is where we stand with tax policy:Kamala Harris and Biden together stated last winter that they would liketo tax long-term capital gains as "ordinary income". So, an IOVA investorin a 24% tax bracket selling his stock would be taxed $2,400 instead of$1,500 for his $10,000 capital gain.But Harris/Biden also don't like Trump's 2017 tax cuts, so letting themexpire next year would turn a 24% marginal tax bracket into a 28% taxbracket and the stock sale would be taxed $2,800. That would almostDOUBLE it! Mr. Trump likes the LT gain tax right where it is at 15%.Harris/Biden have also stated that the top corporate tax rate (the one thataffects IOVA the most) should be increased from 21% currently to 28%, anincrease of 33% on this company that would certainly hurt it's performanceand stock price.Mr. Trump wants to reduce the corporate rate from 21% to 15%. Like the LTgain tax proposals, …...
Votes:
22
6
Yahoo Finance Community
09/18
Comment
If this stock continues to climb in response to rate cuts, then that is great! If this stock decides to fall in response to rate cuts, then I'll be waiting to buy more, which is also great! I really don't see how you can lose here. Good Luck Longs!...
Votes:
10
0
Yahoo Finance Community
09/19
Comment
Believe in this management team. Look what they have accomplished over the past 12 months. Beat street rev and earnings for first Q of sales. Super strong guidance. Assay agreement with fda. Manufacturing site inspection and approval. Nsclc pause lifted in record time. First TIL approval and being administered. Favorable financing. Fired Doris. Record training and approval of over 50 ATC’s. 225 million Americans covered for treatment. EU submission and acceptance. The next 24 months should be spectacular. Trust this management team! Good luck longs....
Votes:
13
1
Yahoo Finance Community
09/19
Comment
A few of the world class partner ATC’s: Georgetown, Duke, UNC. Boston-Dana Farber and Mass Gen. The Ohio State University. Florida-Moffitt, Univ of Miami, Mayo. St Louis-Barnes. Cleveland-Cleveland Clinic. Calif-UCLA, Stanford, Cal SD. Texas-Moffitt, MD Anderson, Baylor Scott. NYC- Sloan Kettering, Cornell, Columbia. Connecticut-Yale. Chicago- univ of Chicago and Northwestern. Pretty good company. And don’t forget, Doris got fired....
Votes:
4
1
Yahoo Finance Community
09/20
Comment
Everybody needs to be patient. They have a great approved drug that is getting tested in so many different cancer types. In addition, they will get approval for international distribution of Amtagvi and start generating revenues next year. This will be a Billion dollar revenue company by 2026 and possibly a Billion dollar run rate by Q3 or Q4 of 25!! Utilize this lull in the stock price to buy more shares and/or buy long term options. Either this will be bought out within the next year or so, or they will become another Big Pharma company. Just the way I’m playing it and see it!...
Votes:
3
0
Yahoo Finance Community
09/24
Comment
Greg, please articulate why you feel the way you do about this management team. Arbitrary words of displeasure doesn’t really hack it. Here is why I believe in this management team. Look what they have accomplished over the past 12 months. Beat street rev and earnings for first Q of sales. Super strong guidance. Assay agreement with fda. Manufacturing site inspection and approval. Nsclc pause lifted in record time. First TIL approval and being administered. Favorable financing. Fired Doris. Record training and approval of over 50 ATC’s. 225 million Americans covered for treatment. EU submission and acceptance. The next 24 months should be spectacular. Trust this management team! Good luck longs....
Votes:
9
2
Yahoo Finance News
09/26
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow Alex Carchidi, The Motley Fool Thu, Sep 26, 2024, 3:15 PM 5 min read In This Article: IOVA +3.89% Now's a great time to build up...
Quantexa News
09/27
Analysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Target Price at $23.00
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marke...
Quantexa News
09/27
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Holdings Lifted by Long Focus Capital Management LLC
Long Focus Capital Management LLC grew its holdings in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 195.1% during the second quarter, according to the company in its most r...
Quantexa News
09/27
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Holdings Lifted by Long Focus Capital Management LLC
Long Focus Capital Management LLC grew its holdings in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 195.1% during the second quarter, according to the company in its most r...
Quantexa News
09/29
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of “Moderate Buy” by Brokerages
Iovance Biotherapeutics, Inc. ( – ) has earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, reports. One equities research analyst...
Quantexa News
09/30
American Century Companies Inc. Decreases Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
American Century Companies Inc. decreased its stake in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 40.0% during the second quarter, according to its most recent 13F filing...
Quantexa News
09/30
American Century Companies Inc. Decreases Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
American Century Companies Inc. decreased its stake in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 40.0% during the second quarter, according to its most recent 13F filing...
Quantexa News
10/02
ProShare Advisors LLC Sells 13,149 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
ProShare Advisors LLC trimmed its stake in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 21.1% in the second quarter, according to its most recent Form 13F filing with the S...
Quantexa News
10/02
ProShare Advisors LLC Sells 13,149 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
ProShare Advisors LLC trimmed its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 21.1% in the second quarter, according to its most recent Form 13F filing with the Sec...
Yahoo Finance Community
10/02
Comment
It has been a pleasure to interact with this message board. However, I can no longer use the Yahoo message boards due to censorship, fact checking and blatant bias towards Kamala and blatant hammering of Trump. Moving to Marketplace and Stocktwirs. Yahoo is cow manure...
Votes:
13
6
Quantexa News
10/03
Xponance Inc. Boosts Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Xponance Inc. raised its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 13.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Co...
Quantexa News
10/03
Xponance Inc. Boosts Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Xponance Inc. raised its stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 13.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange...
Quantexa News
10/04
Squarepoint Ops LLC Buys New Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Squarepoint Ops LLC purchased a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SE...
Yahoo Finance Community
10/04
Comment
I bought $IOVA @ $3.60s awhile back and have great faith that it will contine higher...I am also in the next bio/pharm runner $ESLA @ $1.10s: $ESLA posted startling Trial results last Friday. $ESLA 70% insider owned..Very big play unfolding. $CAPR type move on tap....
Yahoo Finance Community
10/04
Comment
4yr OS with lifileucel. Is now available at 22% - used to be zero for this population. With meds like Pembro and Nivo( which manipulate immune system) there is good data that if patients survive to year 3 without disease, there is more than 90% chance that they will be alive at 10 yrs. Lifileucel is likely to turn out the similar. I attended a meeting where experts involved in the actual study stated - they don’t think lymphodepletion -which causes most toxicities - is not important and there are some studies planned that would be without lymphodepletion. This strategy is yet to be proven but will be interesting....
Votes:
1
0
Yahoo Finance Community
10/04
Comment
Believe in this management team. Look what they have accomplished over the past 12 months. Beat street rev and earnings for first Q of sales. Super strong guidance. Assay agreement with fda. Manufacturing site inspection and approval. Nsclc pause lifted in record time. First TIL approval and being administered. Favorable financing. Fired Doris. Record training and approval of over 50 ATC’s. 225 million Americans covered for treatment. EU submission and acceptance. The next 24 months should be spectacular. Trust this management team! Good luck longs....
Votes:
8
0
Quantexa News
10/05
Dimensional Fund Advisors LP Trims Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Dimensional Fund Advisors LP lessened its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 21.1% during the 2nd quarter, according to its most recent filing with the Securities an...
Quantexa News
10/05
Sei Investments Co. Trims Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Sei Investments Co. decreased its holdings in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 14.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and E...
Quantexa News
10/05
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Position Lowered by Sei Investments Co.
Sei Investments Co. trimmed its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 14.5% in the second quarter, according to its most recent disclosure with the SEC. The institut...
Yahoo Finance Community
10/07
Comment
Did some homework on short interest. Typical company has short interest around 10%. Over 20% is considered very heavily shorted. IOVA is around 20%. The top ten most shorted sticks are all in healthcare; from 21% to 34%. Short interest for pharmaceutical stocks is 6.9%. Short squeeze is more likely if short shares are over 5 days of daily trading volume....
Votes:
3
0
Yahoo Finance Community
10/08
Comment
When IOVA reports its sales soon, I bet you they will beat their guidance. Just thinking they would not put out guidance they did not expect to beat; so, if the market sees this, it will provide support for the other guidance they gave, which may be upgraded. This stock is really de-risked IMO, and headed for some positive news. Please do your own DD and research and don't rely on posters....
Votes:
11
0
Quantexa News
10/09
The Manufacturers Life Insurance Company Sells 23,475 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
The Manufacturers Life Insurance Company lessened its stake in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 6.5% in the 2nd quarter, according to its most recent 13F filing...
Yahoo Finance News
10/09
Strong Investor Sentiment: Artisan Partners Highlights Iovance Biotherapeutics, Inc. (IOVA)
Strong Investor Sentiment: Artisan Partners Highlights Iovance Biotherapeutics, Inc. (IOVA) Minal Zaheer Wed, Oct 9, 2024, 7:03 AM 5 min read In This Article: IOVA -1.46% We recently published a list...
Yahoo Finance Community
10/09
Comment
This is clearly shorts dumping a bunch of shares. They will need to buy these back, but they will try to do this at as low of a price as possible. I wouldn't be surprised if they did this before earnings to drive the price down as low as possible before earnings just to buy right before a massive upswing. Hold your shares and good luck longs....
Votes:
6
1
Yahoo Finance Community
10/09
Comment
I just read that WuXi AppTec will be looking to sell their 4 facilities in Philadelphia due to u s restrictions? I’m guessing somebody will buy them up fast since they have been approved by the FDA to manufacture biologic’s? It takes an average 3 to 5 years to get a facility up running and FDA approved to manufacture biologic from what I understand. Sounds like if they have to sell their facilities and whoever buys them already has one good tenant, IoVance therapeutics?...
Votes:
1
1
Quantexa News
10/10
Is Iovance Biotherapeutics, Inc. (IOVA) the Best Stock Under $10 With High Potential?
We recently compiled a list of 10 Stocks Under $10 With High Potential. In this article, we will look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ranks among the best stocks under $10 with hi...
Yahoo Finance Community
10/10
Comment
I have come to accept that this stock is going to look sad and pathetic...right up until then moment we hit a phase of it looking ridiculously unstoppable.It looks like we are establishing a "new" floor of support at these levels. (fingers crossed)...
Votes:
11
0
Yahoo Finance Community
10/10
Comment
Believe in this management team. Look what they have accomplished over the past 12 months. Beat street rev and earnings for first Q of sales. Super strong guidance. Assay agreement with fda. Manufacturing site inspection and approval. Purchased worldwide rights to Proleukin. Nsclc pause lifted in record time. First TIL approval and being administered. Favorable financing. Fired Doris. Record training and approval of over 50 ATC’s. 225 million Americans covered for treatment. EU submission and acceptance. The next 24 months should be spectacular. Trust this management team! Good luck longs....
Votes:
6
0
Yahoo Finance Community
10/10
Comment
A few of the world class partner ATC’s: Georgetown, Duke, UNC. Boston-Dana Farber and Mass Gen. The Ohio State University. Florida-Moffitt, Univ of Miami, Mayo. St Louis-Barnes. Cleveland-Cleveland Clinic. Calif-UCLA, Stanford, Cal SD. Texas-Moffitt, MD Anderson, Baylor Scott. NYC- Sloan Kettering, Cornell, Columbia. Connecticut-Yale. Chicago- univ of Chicago and Northwestern. Pretty good company. And don’t forget, Doris got fired....
Votes:
7
0
Quantexa News
10/11
B. Riley Wealth Advisors Inc. Makes New Investment in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
B. Riley Wealth Advisors Inc. bought a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fu...
Quantexa News
10/11
B. Riley Wealth Advisors Inc. Acquires New Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
B. Riley Wealth Advisors Inc. acquired a new stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) in the second quarter, HoldingsChannel.com reports. The fund acquired 13,296 shares of...
Yahoo Finance News
10/12
Is Iovance Biotherapeutics, Inc. (IOVA) the Best Growth Stock Under $10 to Buy?
Is Iovance Biotherapeutics, Inc. (IOVA) the Best Growth Stock Under $10 to Buy? Fatima Gulzar Sat, Oct 12, 2024, 9:28 AM 6 min read In This Article: IOVA +2.85% We recently compiled a list of 13 Best...
Quantexa News
10/13
Shaker Investments LLC OH Has $946,000 Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Shaker Investments LLC OH lifted its holdings in shares of Iovance Biotherapeutics, Inc. ( – ) by 27.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securiti...
Quantexa News
10/15
ORG Wealth Partners LLC Invests $89,000 in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
ORG Wealth Partners LLC purchased a new position in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) in the third quarter, according to its most recent filing with the Securities & Exchange...
Quantexa News
10/16
Brookstone Capital Management Grows Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Brookstone Capital Management grew its position in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 43.9% during the 3rd quarter, according to its most recent filing with the Securities...
Yahoo Finance Community
10/16
Comment
We have been trending sideways for the past two months, with small pushes up and down, with a floor hovering around $9.30. Just means no big players are buying yet, but they are not selling either. Ignore this short term nonsense and hold your shares. Q3 earnings will probably be a major catalyst for price action....
Votes:
3
0
Yahoo Finance News
10/16
Is Iovance Biotherapeutics Inc. (IOVA) the Most Promising Stock to Buy According to Wall Street Analysts?
Read full article Insider Monkey Is Iovance Biotherapeutics Inc. (IOVA) the Most Promising Stock to Buy According to Wall Street Analysts? Noor Ul Ain Rehman Wed, Oct 16, 2024, 7:15 PM 8 min read Link...
Quantexa News
10/17
After A 159.37% Jump This Year Is Iovance Biotherapeutics Inc (NASDAQ:IOVA) A Better Buy Than Others?
In recent trading session, Iovance Biotherapeutics Inc (NASDAQ:IOVA) saw 0.48 million shares changing hands at last check today with its beta currently measuring 0.61. Company's recent per share price...
Quantexa News
10/17
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 5.7% – Should You Buy?
Iovance Biotherapeutics, Inc. ( – ) shares rose 5.7% during mid-day trading on Thursday . The company traded as high as $9.90 and last traded at $9.90. Approximately 3,724,556 shares were traded durin...
Quantexa News
10/17
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 5.7% – Should You Buy?
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) shares rose 5.7% during mid-day trading on Thursday . The company traded as high as $9.90 and last traded at $9.90. Approximately 3,724,...
Yahoo Finance News
10/18
State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc
State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc GuruFocus News Fri, Oct 18, 2024, 11:01 AM 3 min read In This Article: IOVA +0.69% STT -1.21% Overview of the Recent Transactio...
Quantexa News
10/18
State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc
Overview of the Recent Transaction State Street Corp, a prominent investment firm, recently expanded its portfolio by acquiring 13,201,978 shares in Iovance Biotherapeutics Inc (NASDAQ:IOVA). This tr...
Quantexa News
10/18
State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc
Overview of the Recent Transaction State Street Corp, a prominent investment firm, recently expanded its portfolio by acquiring 13,201,978 shares in Iovance Biotherapeutics Inc ( NASDAQ:IOVA ). This...
Quantexa News
10/18
State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc
State Street Corp, a prominent investment firm, recently expanded its portfolio by acquiring 13,201,978 shares in Iovance Biotherapeutics Inc ( NASDAQ:IOVA ). This transaction, which took place on Sep...
Quantexa News
10/18
The -13.88% Decline of Iovance Biotherapeutics Inc's (IOVA) Stock in the Past Quarter
In the past week, IOVA stock has gone up by 9.50%, with a monthly gain of 3.04% and a quarterly surge of 28.03%. The volatility ratio for the week is 5.66%, and the volatility levels for the last 30 d...
Quantexa News
10/19
Investors Purchase High Volume of Iovance Biotherapeutics Call Options (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) was the target of some unusual options trading activity on Friday. Traders bought 22,531 call options on the stock. This represents an inc...
Quantexa News
10/19
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Rating of “Moderate Buy” from Analysts
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) have received a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock...
Quantexa News
10/19
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the stock,...
Quantexa News
10/19
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 5.7% – Still a Buy?
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report )'s share price traded up 5.7% on Thursday . The company traded as high as $9.90 and last traded at $9.90. 3,724,556 shares changed hands...
Quantexa News
10/20
Investors Purchase High Volume of Iovance Biotherapeutics Call Options (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) saw some unusual options trading on Friday. Stock traders acquired 22,531 call options on the stock. This is an increase of approximatel...
Quantexa News
10/20
nVerses Capital LLC Acquires Shares of 15,800 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
nVerses Capital LLC bought a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) during the 3rd quarter, HoldingsChannel reports. The fund bought 15,800 shares of the b...
Yahoo Finance Community
10/20
Comment
I think this little run up has a lot more to do with expected material beat and guidance raise. If you listened to the recent fireside chats, mgmt was very bullish on activity. Hoping for a nice raise and even more important, some good updates on expansion into other markets and exciting FDA feedback. Going forward be an exciting two weeks!!!...
Votes:
8
0
Yahoo Finance Community
10/21
Comment
IMGN went through years of share price turmoil and finally started making gains, achieving their first FDA approval and a few quarters later BO… same rhetoric and arguments about the leadership and the company but the longs (some of us 20 years) finally made out! Give it time and IOVA will start making gains! Be savvy and buy more shares in the dips!...
Votes:
14
1
Quantexa News
10/22
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Bought by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC lifted its holdings in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 11.6% in the 3rd quarter, according to the company in its most recent 13F f...
Quantexa News
10/22
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC boosted its stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 11.6% in the 3rd quarter, according to its most recent filing with the SEC. The fund ow...
Quantexa News
10/22
5.53% volatility in Iovance Biotherapeutics Inc (IOVA) last month: This is a red flag warning
Iovance Biotherapeutics Inc (NASDAQ: IOVA) on Monday, plunged -3.12% from the previous trading day, before settling in for the closing price of $10.24. Within the past 52 weeks, IOVA's price has moved...
Quantexa News
10/22
Why Did Iovance Biotherapeutics Inc (IOVA) Stock See 14.15% Surge in the Last 90 Days?
Piper Sandler has recently reduced Iovance Biotherapeutics Inc (IOVA) stock to Neutral rating, as announced on July 29, 2024, according to Finviz . Earlier, on November 20, 2023, Goldman had initiated...
Quantexa News
10/24
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Bought by Vontobel Holding Ltd.
Vontobel Holding Ltd. increased its stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 32.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The...
Quantexa News
10/24
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock Holdings Increased by Vontobel Holding Ltd.
Vontobel Holding Ltd. grew its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 32.5% during the third quarter, HoldingsChannel reports. The institutional investor ow...
Yahoo Finance Community
10/24
Comment
Option players at it again yesterday. Buying a tremendous amount of $10 n $11 calls expiring Nov 15th. Also, a very interesting trade of puts. Somebody bought about 3000 $9 puts expiring on Jan 17, 2025. Looks to me they sold these puts so if the stock goes to that level they would be put the stock, however, the likelihood will be it’s above that price and they keep that $470K. Based on the options, the big guys are setting up for a nice rise imo. Be patient....
Votes:
2
0
Yahoo Finance Community
10/24
Comment
Q3 release will certainly show strong demand. I’m interested in pipeline updates. Including status of manufacturing success improvement. We should be getting the sickest of sick through pipeline. Then need Doc’s getting onboard sooner. Advanced Next Gen manufacturing. The first year learning curve will help to ramp Europe and new indications. GL longs....
Votes:
6
0
Quantexa News
10/24
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.5% – Time to Buy?
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) shares rose 6.5% on Thursday . The company traded as high as $10.48 and last traded at $10.46. Approximately 483,196 shares changed hands...
Quantexa News
10/24
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Now Carries A 12-Month Price Target Of $40.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)'s traded shares stood at 1.06 million during the latest session, with the company's beta value hitting 0.61. At the last check today, the stock's price was $1...
Quantexa News
10/25
Hennion & Walsh Asset Management Inc. Trims Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Hennion & Walsh Asset Management Inc. trimmed its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 4.5% in the 3rd quarter, according to the company in its most recent 13F filing...
Quantexa News
10/26
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of “Moderate Buy” by Analysts
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) have been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, M...
Quantexa News
10/26
Analysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Price Target at $23.00
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) has been assigned an average rating of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat R...
Yahoo Finance Community
10/27
Comment
Lets see if Joe smuc is man enough to admit who made me an enemy on this board.When the stock hit $18. I warned them all it would be taking a step back to $10 . Joe and others called $20 no issues. They also bashed me to no end.WRONG He cost a lot of folks money. I made well over 2 million shorting this back down to $8 with several in and out plays. Even with me being right they hated I made a killing. IBRX has even made me richer of over the last 2 years playing it and accumilating FREE shares with IOVA money now well over 400K shares of IBRX and not selling untill $100...
Quantexa News
10/28
Clear Harbor Asset Management LLC Sells 13,250 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Clear Harbor Asset Management LLC decreased its stake in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 43.0% in the third quarter, according to the company in its most recen...
Quantexa News
10/28
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by Clear Harbor Asset Management LLC
Clear Harbor Asset Management LLC lowered its stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 43.0% during the third quarter, according to its most recent disclosure with the S...
Yahoo Finance Community
10/28
Comment
Believe in this management team. Look what they have accomplished over the past 12 months. Beat street rev and earnings for first Q of sales. Super strong guidance. Assay agreement with fda. Manufacturing site inspection and approval. Purchased worldwide rights to Proleukin. Nsclc pause lifted in record time. First TIL approval and being administered. Favorable financing. Fired Doris. Record training and approval of over 50 ATC’s. 225 million Americans covered for treatment. EU submission and acceptance. The next 24 months should be spectacular. Trust this management team! Good luck longs....
Votes:
3
0
Quantexa News
10/29
$6.02M in average volume shows that Iovance Biotherapeutics Inc (IOVA) is heading in the right direction
A new trading day began on Monday, with Iovance Biotherapeutics Inc (NASDAQ: IOVA) stock price up 3.37% from the previous day of trading, before settling in for the closing price of $10.67. IOVA's pri...
Quantexa News
10/31
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Quantexa News
10/31
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
October 31, 2024 at 16:01 PM EDT SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and del...
Quantexa News
10/31
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
October 31, 2024 at 16:01 PM EDT SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and del...
Quantexa News
10/31
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Iovance also to Participate in Upcoming November Conferences SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on inn...
Quantexa News
10/31
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
October 31, 2024 at 16:01 PM EDT SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and del...
Quantexa News
10/31
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financi
SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Quantexa News
10/31
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
October 31, 2024 at 04:02 pm EDT SAN CARLOS, Calif. Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and deli...
Quantexa News
10/31
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Quantexa News
10/31
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Iovance also to Participate in Upcoming November Conferences SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on inno...
Quantexa News
11/04
Creative Financial Designs Inc. ADV Purchases 8,090 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Creative Financial Designs Inc. ADV increased its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 59.3% during the third quarter, HoldingsChannel.com reports. The fi...
Quantexa News
11/05
Mirae Asset Global Investments Co. Ltd. Raises Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Mirae Asset Global Investments Co. Ltd. boosted its stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 31.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional inv...
Quantexa News
11/05
Mirae Asset Global Investments Co. Ltd. Acquires 2,624 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Mirae Asset Global Investments Co. Ltd. grew its holdings in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 31.4% during the 3rd quarter, according to the company in its most recent fi...
Quantexa News
11/05
47.80% percent quarterly performance for Iovance Biotherapeutics Inc (IOVA) is not indicative of the underlying story
Iovance Biotherapeutics Inc (NASDAQ: IOVA) on Monday, soared 2.23% from the previous trading day, before settling in for the closing price of $11.19. Within the past 52 weeks, IOVA's price has moved b...
Quantexa News
11/07
Beacon Financial Advisory LLC Boosts Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
NASDAQ:IOVA – Free Report ) by 42.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 21,120 shares of the biotechnology company's stock after acquiring an additi...
Quantexa News
11/07
Beacon Financial Advisory LLC Purchases 6,320 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Beacon Financial Advisory LLC grew its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 42.7% in the 3rd quarter, according to its most recent 13F filing with the Sec...
Yahoo Finance News
11/07
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. Thu, Nov 7, 2024, 3:01 PM 23...
Yahoo Finance News
11/07
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates Zacks Equity Research Thu, Nov 7, 2024, 5:45 PM 3 min read In This Article: IOVA -13.31% Iovance Biotherapeutics (IOVA) came out...
Quantexa News
11/07
Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Sara Pellegrino - Senior Vice President, Investor Relations and Corporat...
Quantexa News
11/08
Q3 Earnings Estimate for IOVA Issued By HC Wainwright
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) – Stock analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for Iovance Biotherapeutics in a research note issued to...
Yahoo Finance News
11/08
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ...
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ... GuruFocus News Fri, Nov 8, 2024, 7:03 AM 4 min read In This Article: IOVA -13.80% Total Product Revenue (Q3...
Quantexa News
11/08
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
Iovance Biotherapeutics, Inc. IOVA Quick Quote IOVA Free Report ) incurred a third-quarter 2024 loss of 28 cents per share, narrower than the Zacks Consensus Estimate of a loss of 31 cents. In the yea...
Yahoo Finance News
11/08
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line Zacks Equity Research Fri, Nov 8, 2024, 9:11 AM 6 min read In This Article: IOVA -13.80% Iovance Biotherapeutics, Inc. IOVA incu...
Quantexa News
11/08
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
Iovance Biotherapeutics, Inc. IOVA incurred a third-quarter 2024 loss of 28 cents per share, narrower than the Zacks Consensus Estimate of a loss of 31 cents. In the year-ago quarter, the company repo...
Quantexa News
11/09
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) Q3 2024 Earnings Call Transcript November 7, 2024 Iovance Biotherapeutics, Inc. beats earnings expectations. Reported EPS is $-0.27547, expectations were...
Yahoo Finance News
11/09
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year editorial-team@simplywallst.com (Simply Wall St) Sat, Nov 9, 2024, 8:35 AM 3 min r...
Quantexa News
11/09
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
editorial-team@simplywallst.com (Simply Wall St) 3 min read In this article Iovance Biotherapeutics, Inc. NASDAQ:IOVA ) just released its quarterly report and things are looking bullish. Iovance Bi...
Quantexa News
11/09
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Iovance Biotherapeutics, Inc. NASDAQ:IOVA ) just released its quarterly report and things are looking bullish. Iovance Biotherapeutics beat expectations with revenues of US$59m arriving 8.8% ahead of...
Quantexa News
11/10
Research Analysts Issue Forecasts for IOVA Q3 Earnings
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) – Research analysts at HC Wainwright issued their Q3 2024 EPS estimates for shares of Iovance Biotherapeutics in a research report issued to...
Quantexa News
11/10
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down – Here’s Why
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $12.28, but opened at $10.67. Iovance Biotherapeutics...
Quantexa News
11/10
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down – Time to Sell?
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $12.28, but opened at $10.67. Iovance Biotherapeutics...
Quantexa News
11/12
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired by Principal Financial Group Inc.
Principal Financial Group Inc. increased its position in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 59.0% in the 3rd quarter, according to its most recent disclosure with...
Quantexa News
11/12
XML Financial LLC Raises Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
XML Financial LLC increased its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 7.4% during the third quarter, according to the company in its most recent disclosure wi...
Quantexa News
11/12
XML Financial LLC Acquires 1,000 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
XML Financial LLC increased its stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 7.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchang...
Quantexa News
11/12
HC Wainwright Has Optimistic Outlook of IOVA FY2027 Earnings
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) – Analysts at HC Wainwright lifted their FY2027 earnings estimates for shares of Iovance Biotherapeutics in a research report issued on Frid...
Yahoo Finance News
11/12
Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations
Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations editorial-team@simplywallst.com (Simply Wall St) Tue, Nov 12, 2024, 10:50 AM 1 min read In This Article: IOVA -7.07% Iovance Bio...
Quantexa News
11/12
HC Wainwright Has Positive Estimate for IOVA FY2027 Earnings
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) – Equities researchers at HC Wainwright lifted their FY2027 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a repo...
Quantexa News
11/13
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of “Moderate Buy” by Analysts
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports...
Quantexa News
11/14
Ryan D. Maynard Sells 50,000 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) Director Ryan D. Maynard sold 50,000 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at...
Quantexa News
11/14
Ryan D. Maynard Sells 50,000 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) Director Ryan D. Maynard sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were...
Quantexa News
11/15
Iovance Biotherapeutics Inc (IOVA) recent quarterly performance of -18.19% is not showing the real picture
Iovance Biotherapeutics Inc (NASDAQ: IOVA) started the day on Thursday, with a price decrease of -4.56% at $8.59, before settling in for the price of $9.00 at the close. Taking a more long-term approa...
Quantexa News
11/15
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Director Ryan D. Maynard Sells 50,000 Shares
NASDAQ:IOVA – Get Free Report ) Director Ryan D. Maynard sold 50,000 shares of the business's stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $10.06, f...
Quantexa News
11/16
Brokerages Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Price Target at $22.33
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) has been given an average rating of “Moderate Buy” by the nine research firms that are currently covering the firm, Marketbeat.com repor...
Quantexa News
11/16
Brokerages Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Target Price at $22.33
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat.com rep...
Quantexa News
11/18
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine analysts that are presently covering the company, Market...
Yahoo Finance Community
11/18
Comment
What I’m glad to know about IOVA is that management doesn’t treat the work like a science project (which I know both as an investor and biotech employee that many companies do). It’s very obvious that everything is done for ultimate product delivery, not merely for the sake of scientific research (yes, you’d be surprised how much money is spent on the latter at some companies)....
Votes:
2
0
Yahoo Finance Community
11/18
Comment
A week in the life of an IOVA investor:Day 1: Wake up to -10% -> Cope about this being a "smart" longterm investment.Day 2: Wake up to -10% -> Attack any and all criticism of the company. Continue convincing yourself that this is a longterm investment. Buy the "dip".Day 3: Wake up to -10% -> Start attacking the management for doing nothing to stop the drop. Continue "buying the dip" and tell everyone that this is a "steal", and that they should buy this and order their lambo (Which is impossible considering all the networth is in the IOVA moneypit).Day 4: Wake up to +3% -> Hit the bears with "I told you so", only for the stock to crater to -6% at the end of the day. Wife leaves you for being this gullible. You get an advance payday loan to "buy the dip".Day 5: wake up to a …...
Votes:
4
3
Quantexa News
11/18
Stock Traders Buy Large Volume of Iovance Biotherapeutics Call Options (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) saw unusually large options trading on Monday. Investors acquired 17,736 call options on the stock. This is an increase of 71% compared...
Yahoo Finance Community
11/19
Comment
Couple large transactions were reported after hour. I believe these are shares transferred to ultimate buyer at the end of the day. Agent acquired shares throughout the day on behave of the buyer, and make a transfer to the buyer at the end of day. Not sure if these are adding positions or closing short positions. I do not know how to read if the buying were at the bid price or ask price. For the day, stock was up....
Votes:
1
2
Yahoo Finance Community
11/19
Comment
Down 34% since earnings, of which they beat expectations. How’s everybody feeling about management? Does everyone agree with their constant use of dilution tactics? All their reported accomplishments and yet the valuation is less today than it was five years ago. Incomprehensible....
Votes:
4
3
Quantexa News
11/20
Iovance Biotherapeutics Sees Unusually High Options Volume (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) saw unusually large options trading activity on Monday. Stock investors acquired 17,736 call options on the company. This is an increase...
Quantexa News
11/20
Analysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) PT at $22.33
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) have been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are covering the stock, Marketbeat re...
Quantexa News
11/20
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Could Post Excellent Profits?
In the last trading session, 6.3 million shares of the Iovance Biotherapeutics Inc (NASDAQ:IOVA) were traded, and its beta was 0.56. Most recently the company's share price was $8.19, and it changed a...
Quantexa News
11/20
30,070 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Bought by Grandfield & Dodd LLC
Grandfield & Dodd LLC bought a new stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commi...
Quantexa News
11/20
Grandfield & Dodd LLC Invests $282,000 in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Grandfield & Dodd LLC bought a new stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) in the third quarter, Holdings Channel reports. The fund bought 30,070 shares of the biotechnolo...
Yahoo Finance Community
11/20
Comment
MIST; $1.75; Upon potential approval of its tachycardia heart drug we should see a market cap of $400 - $600M and a share price of $10 - $15. This reflects a conservative approach, using 3 x US revenue potential and neglecting the pipeline value and outside US market opportunities. A non-dilutive financing to support the launch is already in place. Moreover, we have been in a very narrow trading range of about 1,50$ for 10 months which was just broken with a strong upside move and with increasing trading volume and public visibility. Technically at a golden cross, signaling a major breakout. More buzz on the street will follow, driving the share price appreciation further. No risk for bad news in the near term and solid financials with ample cash on hand....
Votes:
1
2
Yahoo Finance Community
11/20
Comment
This is a 1x time treatment with durability and increasing efficiency over time. No weekly trips for radiation and chemo and switching drugs as efficacy/durability halts. 4001 and 5001 coming with better results and easier on patient. Eventually a frontline multi tumor therapy....
Votes:
10
1
Yahoo Finance Community
11/20
Comment
This will get bought out. It’s just a matter of time imo. Not easy, but continue to accumulate shares and LEAPS and you’ll be sitting pretty when the buyout comes to fruition!! Could be six months, a year, two or more. Need to be patient. Just my opinion and how I’m playing it....
Votes:
7
1
Yahoo Finance Community
11/21
Comment
Vivek Ramaswamy has criticized the FDA for creating excessive regulatory hurdles throughout the drug development process. He contends that the FDA’s approach extends beyond final approval decisions, effectively gatekeeping innovation at every stage, from preclinical testing to human trials. This control, he claims, not only delays patient access to potentially life-saving therapies but also discourages bold new approaches within the pharmaceutical industry. Will he get his way to make the FDA more streamlined? Will he have major influence? He could have the most influence with Trump on the FDA.Vivek's wife is a cancer researcher, professor at Ohio State University, and serves on the medical advisory board of a National Foundation. Could she head the FDA?...
Votes:
6
1
Quantexa News
11/21
LMR Partners LLP Has $387,000 Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
LMR Partners LLP decreased its holdings in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 32.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 41,211 shares of t...
Quantexa News
11/21
A peek at Iovance Biotherapeutics Inc (IOVA): Who has invested in It?
Iovance Biotherapeutics Inc (NASDAQ: IOVA) is 0.12% higher on its value in year-to-date trading and has touched a low of $5.14 and a high of $18.33 in the current 52-week trading range. The question b...
Yahoo Finance Community
11/21
Comment
This sell off was nothing more than risk off on the entire biotech sector since the election and RFK nomination. just look at any biotech chart, its identical to IOVA. XBI has bottomed and its reversing and the rest of biotechs will follow. In addition the gap at $8 has been filled today. How shocking IOVA is now moving up. I've been adding this week in the low $8's and anyone else that buys now will be rewarded. Earning were sold and holding here is low risk trade, dont let Scam St. scare you. Be greedy when others are fearful. GL....
Votes:
12
0
Yahoo Finance Community
11/21
Comment
I am amazed how this board resembles real society. I watch some individuals brag how they make money betting against people supporting, promoting, and trying to share the success of life-saving companies. I dont mind if they make money but i do despise the fact they enjoy seeing the pain of decent people who believe in investing in the common good of society. This is what the stock market is supposed to be. This is not capitalism (which I believe in), this is good against evil. Sad......
Votes:
15
0
Yahoo Finance Community
11/21
Comment
Just read Iovance's 8K filing. Looks like they are downsizing their HQ's to a smaller office at less than half the cost. Going from around $245k per month to around $100k per month. So they'll save money--but to me, the bigger piece here is that Iovance EXPECTS to be sold in the next 24 months (the term of the new lease) and thus, won't need a long-term lease or such a big office! All that will move over to Merck's HQ's or whichever BP buys them. I can wait two years for a $42 share price....
Votes:
9
3
Yahoo Finance Community
11/22
Comment
I’m long with stock and leap calls. This will be range bound until it starts selling in Europe and Australia. Couple that with some good news eventually on the non-small cell lung cancer and that’s when it will start moving. Hopefully we get a nice up trend in six months to a year. Now is the time to accumulate....
Votes:
7
0
Quantexa News
11/22
Iovance Biotherapeutics Signs New Headquarters Lease and Terminates Previous Lease Agreement
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a Delaware-based biotechnology company, has recently announced significant changes in its office locations and lease agreements. On November 15, 2024, the...
Quantexa News
11/22
Iovance Biotherapeutics Signs New Headquarters Lease and Terminates Previous Lease Agreement
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a Delaware-based biotechnology company, has recently announced significant changes in its office locations and lease agreements. On November 15, 2024, the...
Yahoo Finance Community
11/22
Comment
DOA - They blew it. Wait. But they reduced the vending machine area. Ok, Ok, I'm back in. Breaktime. Now that I don't have to deal with as many ppl on break (stealing my hot sauce from the communal fridge), the nsclc should come through right?! Is that rational? Keep holding the bag for good old Wayne who is NoT on your side (in case you haven't noticed). He's in bed with the same ppl who short the stock and buy the calls. It's what is known as an A-B relationship. C yourself out of it. I really believed until I didn't. Time is $$ and I don't have time to wait (or get diluted all the way along). Classic biotech. Great stories. Kinda like the promises Vegas gives.......
Votes:
3
8
Yahoo Finance Community
11/23
Comment
So the new FDA commissioner will be a surgical oncologist - in the right field for cancer care Any thoughts if he will be friendly to companies advocating immunotherapy and cutting red tape so that a drug doesn't have to take an excessive amount of time to get to market ?...
Votes:
4
0
Yahoo Finance News
11/23
Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds
Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds Sheryar Siddiq Sat, Nov 23, 2024, 9:31 AM 6 min read In This Article: IOVA +3.76% We recently comp...
Quantexa News
11/23
Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds
We recently compiled a list of the In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against the other promising cancer stocks. According to the...
Quantexa News
11/23
Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands ag...
Quantexa News
11/23
Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds
We recently compiled a list of the In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against the other promising cancer stocks. According to the...
Polygon News
11/23
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
Iovance Biotherapeutics, a rising star in the cell therapy biotech industry, is seeing strong sales of its approved cancer treatment Amtagvi, with revenue expected to triple in the near term. The comp...
Quantexa News
11/24
GSA Capital Partners LLP Buys Shares of 25,824 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
GSA Capital Partners LLP purchased a new stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The firm pur...
Quantexa News
11/24
Landscape Capital Management L.L.C. Makes New $615,000 Investment in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Landscape Capital Management L.L.C. bought a new stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought...
Yahoo Finance Community
11/25
Comment
The puff piece articles are meaningless to savvy investors but that said, there were three the past few days telling the world how great this stock is. Any IOVA Long knows this already. Price is where it was prior to approval and yet, derisked, almost $500M in revenues next year and many more positive reports coming this year ahead. Buy and hold......
Votes:
11
0
Yahoo Finance Community
11/25
Comment
Q4 release probably something like “as you can see, the adoption is strong in the marketplace. ATC efficiency continually improving. Patients getting to TIL much earlier. Patient selection improving margins. As a result, raising guidance for 2025 which doesn’t include any overseas revenue. Finally, the ATM is done and cash on hand is more than sufficient to reach positive cash flow. “...
Votes:
8
0
Yahoo Finance News
11/26
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer Iovance Biotherapeutics, Inc. Tue, Nov 26, 2024, 1:01 PM 8 min read In This Article: IOVA +4.44% Io...
Quantexa News
11/26
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
SAN CARLOS, Calif. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclon...
Quantexa News
11/26
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...
Yahoo Finance News
11/26
Iovance Biotherapeutics Names Raj Puri as Chief Regulatory Officer
PREMIUM Iovance Biotherapeutics Names Raj Puri as Chief Regulatory Officer MT Newswires Tue, Nov 26, 2024, 1:54 PM In This Article: IOVA +4.44% Iovance Biotherapeutics (IOVA) said late Tuesday it appo...
Quantexa News
11/26
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
November 26, 2024 at 16:01 PM EST SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, develop...
Quantexa News
11/26
Iovance Biotherapeutics (IOVA) Promotes Raj Puri to Chief Regulatory Officer
November 26, 2024 4:02 PM EST Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) today announced that Raj Puri, M.D., Ph.D. has been promoted to the newly created role of Chief Regulatory Officer. Dr. Pur...
Quantexa News
11/26
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...
Quantexa News
11/26
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...
Quantexa News
11/26
Iovance Biotherapeutics Promotes Raj Puri to Chief Regulatory Officer
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) today announced that Raj Puri, M.D., Ph.D. has been promoted to the newly created role of Chief Regulatory Officer. Dr. Puri joined Iovance in March 2022...
Quantexa News
11/26
Iovance Biotherapeutics, Inc. Announces the Promotion of Raj Puri to Chief Regulatory Officer
Iovance Biotherapeutics, Inc. announced that Raj Puri, M.D., Ph.D. has been promoted to the newly created role of Chief Regulatory Officer. Dr. Puri joined Iovance in March 2022 as Executive Vice Pres...
Quantexa News
12/02
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Update
Iovance Biotherapeutics, Inc. ( – ) was the target of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 53,990,000 shares, a drop of...
Quantexa News
12/02
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Large Decrease in Short Interest
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) saw a significant decline in short interest in November. As of November 15th, there was short interest totalling 53,990,000 shares, a de...
Yahoo Finance News
12/03
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63%
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63% editorial-team@simplywallst.com (Simply Wall St) Tue, Dec 3, 2024, 4:27 AM 4 min read In This Arti...
Yahoo Finance Community
12/04
Comment
This is institutions and MM doing what they do to retail investors. They’ll walk it down and most retail will throw up their hands and walk away. Then it will eventually skyrocket n retail will buy back in at top. Be patient and accumulate on dips and if you’re into options, only buy LEAPS. Just my Opinion and how I’m playing it....
Votes:
13
1
Yahoo Finance Community
12/05
Comment
there is alot of complaining on here and i get it. you shouldn't be looking at the daily moves here- just like wayne roathbaum. his shares were worth nearly 600M back in February and now they are worth around 300M and your complaining? LOL- if he didn't sell- the same example can be said about Edelman at perceptive- you shouldn't. they are clearly expecting a WAY bigger move, whether it is a buyout or natural growth. Wayne is a genius and is a very conservative investor. he doesn't take risks he will lose on. take advantage of the irational biotech winter while you can, because we will be testing XBI 2021 highs soon!...
Votes:
8
0
Yahoo Finance Community
12/06
Comment
I have no issue seeing the share price drop to 7$ as the SP will be sooner or later (1, 2, 3 years...) > 20. Anyone who argues that it is not worth holding to a share that has a risk of dropping by 1.5 $ vs. an ×10 upside of 15$ equivalent to 200% ROI in less than 3 years should get his brain checked......
Votes:
13
0
Yahoo Finance Community
12/06
Comment
In the past few weeks short interest has dropped over 10%, currently 54 M outstanding down from 60+ M, the norm for most of the last few years.IOVA keeps providing top cover through daily dilutions, it is after all, fundamentally an R&D outfit, however it looks like even the shorts are preparing for a viable biz in the coming months....
Votes:
12
0
Yahoo Finance Community
12/07
Comment
we are trading at 2 times 2028 revenue- the lowest amongst biotechs with a market cap between 1B and 7B. this is excluding potential nsclc approval, further expansion ex us and any other positive indications from the 10+ clinical trials. TIL therapy is as paradigm shifting to cancer as AI is to technology or as GLP1 is to weight loss. There is truly no short thesis here, buy and hold at these basement prices!...
Votes:
6
1
Yahoo Finance Community
12/07
Comment
Given the depth of the clinical pipeline and its dependence on the iCTC, let alone Amtagvi, combined with the offering last Feb. at $9/share, a near term buy out would basically be a sign of surrender. Under this scenario, there would be no premium, as the buyer would be assuming the risk that IOVA failed at.It's pretty clear from the earnings calls this past year, there is no surrender in the current team, and each quarter they have made improvements in their performance, including COGS, gross margins, and revenues. They are still a ways out on covering their burn, but IOVA is headed in the right direction and given the low multiples pointed out below, the strategy here should be self evident....
Votes:
12
0
Quantexa News
12/08
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) have earned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat re...
Quantexa News
12/09
Iovance Biotherapeutics Inc (IOVA) Looks Ready for Growth Despite 11.07% Change This Year
Iovance Biotherapeutics Inc (NASDAQ: IOVA) is 11.07% higher on its value in year-to-date trading and has touched a low of $6.00 and a high of $18.33 in the current 52-week trading range. The question...
Quantexa News
12/11
Analysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Target Price at $22.33
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are covering the firm, Marketbeat Ra...
Quantexa News
12/11
BNP Paribas Financial Markets Cuts Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
BNP Paribas Financial Markets decreased its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 75.5% during the third quarter, according to the company in its most rece...
Quantexa News
12/11
BNP Paribas Financial Markets Cuts Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
BNP Paribas Financial Markets decreased its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 75.5% during the third quarter, according to the company in its most rece...
Quantexa News
12/11
Investors finally get a glimpse of Iovance Biotherapeutics Inc (IOVA) volume hitting the figure of 4.2 million.
A new trading day began on Tuesday, with Iovance Biotherapeutics Inc (NASDAQ: IOVA) stock price down -3.91% from the previous day of trading, before settling in for the closing price of $8.94. IOVA's...
Yahoo Finance Community
12/12
Comment
it is always darkest before the dawn. the one word I can use to describe our price movement since those knockout earnings is: irrational. once what is coming actually happens, all of the awkwardness we are seeing in price action will make sense. the market is manipulated- that is not coming from a place of contempt- as small retail guys there is nothing we can do to change that. but from my years of observation, when something is so promising yet so manipulated, the run up is even bigger. if you have read Wayne's book, you would know he has made numerous enemies through the deals he was a part of who quite frankly don't want to see him alive anymore. they are shorting this stock to smithereens to try to the make the process more difficult for him. hence the run up from 3 to 18, shorts covering and …...
Votes:
9
1
Yahoo Finance Community
12/12
Comment
This is just pure institutions and MM trying to get as many cheap shares as possible, hedge their long positions, gain as much premium as possible and force retail to sell. They know IOVA will be acquired but it will take longer than most retail can withstand. Just how I see it. Patients def needed. Wouldn’t be shocked if they drop this below $8....
Votes:
5
0
Yahoo Finance Community
12/12
Comment
Opdivo, the Bristol Myers treatment for advanced, metastatic melanoma, has a 5year plus survival over 50%. The keytruda/Moderna vaccine for advanced melanoma is super promising. These are both much cheaper than Amtagvi, and the Moderna vaccine has much less side effects. Am I missing something?...
Votes:
4
2
Quantexa News
12/12
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Stock Dropped -14.29% Over A Month – Is There Any Hope Of A Gain?
During the recent session, Iovance Biotherapeutics Inc (NASDAQ:IOVA)'s traded shares were 0.88 million, with the beta value of the company hitting 0.53. At the last check today, the stock's price was...
Yahoo Finance Community
12/12
Comment
Yup. I know this isn't an airport, and I need not announce my departure but...I'm going to take the tax loss on my current shares and revisit building a new position later.See you in 60 days! And if it surges immediately after I sell.... you're welcome.(I always find that superstition to be wildly narcissistic). Good luck longs.Good luck Iovance....
Votes:
14
0
Yahoo Finance Community
12/12
Comment
Come on gang, you know who’s selling, almost 250 k bought around 11:00. I’d buy more put I’m maxed out. Time to check the very high AH as of late. And who bought 5000 calls last week that expire tomorrow? Hard to ignore but pop a cork and TNF, maybe light a fatty...
Votes:
5
0
Quantexa News
12/13
20,000 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Bought by SkyView Investment Advisors LLC
SkyView Investment Advisors LLC bought a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) during the 3rd quarter, according to its most recent 13F filing with the SE...
Quantexa News
12/13
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Metrics That Matter Right Now
Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares, rose in value on Thursday, December 12, with the stock price down by -7.23% to the previous day's close as strong demand from buyers drove the stock t...
Quantexa News
12/16
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Large Growth in Short Interest
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 56,920,000...
Quantexa News
12/16
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Update
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) saw a significant growth in short interest in November. As of November 30th, there was short interest totalling 56,920,000 shares, a growt...
Quantexa News
12/16
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Large Growth in Short Interest
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 56,920,000...
Polygon News
12/17
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
The article discusses two biopharma stocks, CRISPR Therapeutics and Iovance Biotherapeutics, that are expected to see significant gains in 2025. It analyzes the potential drivers for their growth and...
Quantexa News
12/17
Iovance Biotherapeutics Inc (IOVA) Shares Up Despite Recent Market Volatility
Iovance Biotherapeutics Inc (NASDAQ: IOVA) has seen a rise in its stock price by 0.13 in relation to its previous close of 7.83. However, the company has experienced a -12.30% decline in its stock pri...
Quantexa News
12/18
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Large Increase in Short Interest
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) saw a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 56,920,000 shares...
Quantexa News
12/18
Short Interest in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Increases By 5.4%
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 56,920,000 shares, an increase...
Yahoo Finance Community
12/18
Comment
I increased my position 29% today. Not because I believe in management but because I believe in the technology. For the sake of all those that can benefit including patients and shareholders it’s critical this clueless management including worthless Wayne stop being selfish and turn the technology over to a team who can manage its future. They bit way more than they can chew. If Wayne had any confidence he’d increase his position....
Votes:
1
4
Yahoo Finance News
12/20
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Iovance Biotherapeutics, Inc. Fri, Dec 20, 2024, 3:00 PM 7 min read In This Article: IOVA +2.22% Iovance Biothera...
Polygon News
12/20
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, a biotechnology company, announced the grant of inducement stock options to 48 new, non-executive employees. The options have an exercise price of $7.22 and vest over a three-...
Yahoo Finance Community
12/21
Comment
DCF model indicates a 46% upside from here. Price tarket $10.93 and assumes terrible gross margins. If they are able to manufacture without exploding CoS then it could go a lot higher. May also overshoot on momentum. But high manufacturing costs of autologous medications may be the Achilles heel here?...
Votes:
3
0
Yahoo Finance Community
12/21
Comment
Motley Fool article author suggests the company would exceed 1 billion in revenue by 2030. Except, that will happen by 2027. Maybe 2026. If this company is not doing 3 billion in revenue by 2030, they are in trouble. By then they will be bought out at $42. We are close to a 52 week low, and yet prospects have never been stronger. Major disconnect. Major buying opportunity....
Votes:
7
1
Yahoo Finance Community
12/21
Comment
Thanks for pointing me here. I’m a huge believer in the power of immunotherapy and I love companies that have at least one approved drug already. The fundamentals here look solid and the concept is sound, I can imagine some of the ongoing trials will hit. Will buy some shares for Christmas....
Votes:
3
0
Yahoo Finance Community
12/24
Comment
Market flying and IOVA doing what it does best and disappointing its investors. For what should have went down as an epic year, it will go down as the dud of the year. Thanks management, we appreciate the endless dilutions especially going about it with a sneaky ATM. We end the year hovering around a 52 week low. Well done! Happy Holidays everyone....
Votes:
2
1
Yahoo Finance Community
12/24
Comment
Merry Christmas all! Maybe someone inside IOVA will stop leaving fake Glassdoor reviews and they can actually hire the 100 + open positions they still have that no one wants. Nothing makesa stock soar like not having enough headcount to execute your business objectives....
Votes:
2
2
Yahoo Finance Community
12/25
Comment
Both Iovance and ImmunityBio have disappointed. I got back in Iovance, which I sold at 14. Foolishly I did not sell Immunity, and now hold a 50% bag. Lesson learned in Bio 2024. Never, ever, hold Bio long. Retail are not investors, should not see themselves as investors. Companies do not see retail as investors. We, common folk, are flees that can ride a dog, but before we know it the owner will wash us away. Take ImmunityBio, the CEO gave a 35% discount to whomever bought his last offering. Iovance, did what every Bio does, raise capital after PDUFA because the sales and marketing process is extremely expensive. Even in their last PR they stated that projected 2025 revenue including current cash balances will run operations up to Q1 2026 only. I got back into Iovance as their businessmodel seems unsustainable, and thus must partner. The same I expect …...
Votes:
5
5
Yahoo Finance Community
12/26
Comment
Same 56M or so short shares, but just looked at debt to equity ratio which is very positive. $378M in cash, only $78M in debt. Yes, most of that cash was raised during offerings but that is already priced into the SP. I'm adding more at these prices however, I am adding in the form of 2026 calls, mixed between $5 and $10. Did that at approval for a huge gain, and I think this goes back to that $17 range a year from now. A BO would be a bonus....
Votes:
7
0
Yahoo Finance Community
12/27
Comment
I have seen this type of trend so many times where a good company with a good product will plunge 60-70% after the fda approval. Then one morning you wake up and the company has been acquired with 5-10x the current price. Don’t be surprised one day you wakes up and IOVA is gone, jst saying....
Votes:
15
0
Quantexa News
12/29
Franklin Resources Inc. Raises Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Franklin Resources Inc. grew its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 9.2% during the 3rd quarter, according to its most recent Form 13F filing with the S...
Yahoo Finance Community
12/31
Comment
So here we are, 2024 to a close, and IOVA sits below the SP of exactly a year ago, before approval, before projected $475M in 2025 revenues, before Lung off of trial-halts and before EU, frontline and other approvals and initiatives. I agree with burner below, it's before the grubby shorts got their mitts onto this stock and hold it down with their kung foo grips. I believe big things are ahead starting in 2025 and we'll see a doubling of SP by summer if not sooner. Happy New Year to all longs and all the best for 2025!...
Votes:
11
0
Quantexa News
01/01
Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 52-Week Low – Should You Sell?
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s stock price reached a new 52-week low on Monday . The company traded as low as $7.05 and last traded at $7.16, with a volume of 1018130...
Yahoo Finance Community
01/01
Comment
Long-term investors, I encourage you to make the Iovance webpage a place you visit on a regular basis to gather information about the company you own. E.g., there are currently exactly 100 jobs posted for employment. 100. Many smaller biotechs lack even 100 employees, much less postings. Great presentations exist showing the stages and updates on their deep pipeline and status of frontline Melanoma treatment--expect to "add thousands of patients to the therapy each year." Thousands. At $515,000 each. Each "thousand" is a half bil alone in revenue. We've not even factored in Lung, Cervical and many other treatments in their deep pipeline. Yes, we're all frustrated with shorts and the current SP, below even price at approval. But news on Frontline, Europe and other treatments will announce this year ahead (yes, Happy New Year!) that will drive SP higher. Much higher. Buy, hold, be patient. You'll kick yourself for …...
Votes:
17
0
Yahoo Finance Community
01/02
Comment
Never fails to make me smile.It's been almost a year of IOVA bulls claiming that the pump/buyout/revenue will come any day. "This is the last chance below $8 a share" comments come on every rare occasion where IOVA gets a single green day.I guess you gotta take any small win you can (despite being heavily in the red still)...
Votes:
6
1
Quantexa News
01/02
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.7% – Should You Buy?
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) shot up 7.7% on Thursday . The stock traded as high as $7.99 and last traded at $7.97. 2,429,683 shares traded hands during mid-...
Yahoo Finance News
01/02
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today
Read full article Motley Fool Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today Eric Volkman, The Motley Fool Thu, Jan 2, 2025, 6:03 PM 2 min read Link Copied 0 Now this is a fine way...
Yahoo Finance Community
01/03
Comment
Come on people, have faith don't sell your shares. IOVA on the verge of saving many lives in the world. Once they get their footing they will be off to the races. Hold onto your shares. I have, even after this horrible selloff because I believe in their technology. Once Europe and others see they value, more will jump on board....
Votes:
4
0
Yahoo Finance News
01/03
Exploring 3 High Growth Tech Stocks In The United States
Exploring 3 High Growth Tech Stocks In The United States editorial-team@simplywallst.com (Simply Wall St) Fri, Jan 3, 2025, 12:02 PM 4 min read In This Article: IOVA -1.80% FUFU +1.43% FUFUW -0.18% AP...
Yahoo Finance Community
01/03
Comment
I saw that piece today on Good Morning America. They gave a good overview of the therapy and how it’s already saving lives. The young mother they profiled was out of options when her cancer returned but now the tumor is reduced 50% with the treatment. Those 2024 smiling Christmas photos show how happy she and her family are for her new lease on life. Thanks Iovance!! Have patience longs. This is gonna be huge...
Votes:
16
0
Yahoo Finance Community
01/03
Comment
I sold all my IBRX this morning and poured the money right into IOVA. I believe TILs with their targeted cell therapies for different tumors will revolutionize the way oncologists treats cancer. If IOVA doesn’t get bought out by a in 2025 BP will have to pay a lot more in 2026 and beyond where they will have multi billion dollars in sales, and that is, if IOVA doesn’t decide to go at it alone as they keep getting accelerated approvals for a new mechanism of action that the FDA seems to appreciate. It’s only my opinion but I’m looking forward to seeing cancer being a curable disease in the near future and us investors profiting from a good cause. GLTA Long Investors....
Votes:
15
0
Quantexa News
01/04
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.7% – Still a Buy?
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) shot up 7.7% during trading on Thursday . The company traded as high as $7.99 and last traded at $7.97. 2,429,683 shares chang...
Quantexa News
01/07
These Numbers Show Favorable Signs for Iovance Biotherapeutics Inc (IOVA)
Iovance Biotherapeutics Inc (NASDAQ: IOVA) is 1.08% higher on its value in year-to-date trading and has touched a low of $7.05 and a high of $18.33 in the current 52-week trading range. The question b...
Yahoo Finance Community
01/07
Comment
This stock trading is happening like a clock work. They bring it down in the morning and back up in the afternoon with the price staying flat. You see the games being played. The patience will be rewarded eventually. It is just a matter of time. This is an easy double from here in 2 years....
Votes:
3
0
Yahoo Finance Community
01/07
Comment
Pure speculation but with MRK buying the Wuxi vaccine plant in Ireland could they manufacture TIL there? Could that be an added bonus to the purchase along with their own manufacturing of vaccines? Probably not related but would be nice with all of Iovance's expansion into the Europe...
Votes:
4
1
Quantexa News
01/08
Iovance Biotherapeutics Faces Market Pressures with Low Stock
Author Ryan Hughes Updated : 01-08-2025 12:41 PM Market Challenges Impact Iovance Biotherapeutics In a challenging market environment, shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have re...
Quantexa News
01/08
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low - What's Next?
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $7.05 and last traded at $7.05, wit...
Yahoo Finance Community
01/08
Comment
this is completely irrational. from My experience when an artifical walkdown occurs like this with only good news in sight there are two possibilities: 1. a buyout is coming 2. bankruptcy is coming and the market makers know it but retail doesn't. you choose which one seems more likely 🤷♂️...
Votes:
4
1
Yahoo Finance Community
01/08
Comment
No buyout near term. Those that control want much more than buyers willing to pay….now. No bankruptcy. No debt and small chance therapy gets pulled from market. 4 Q reports and maybe 2 other meaningful news events per year. All of those timing is known. So company blocks and tackles while shorts and call writing keep stock depressed with little risk. Overseas approvals, Tilvance and especially nsclc changes all of this. Don’t forget, company cash runway estimate doesn’t include any UK or EU revenue....
Votes:
14
0
Polygon News
01/09
Immunotoxins Market Trends and Regional Business Opportunities, 2024-2034: Diphtheria Toxin-Based Immunotoxins Lead Revenue, Pseudomonas Exotoxins Show Rapid Growth Potential
The global immunotoxins market is projected to grow at a CAGR of 8.11% from 2024 to 2034, driven by the rising prevalence of malignancies, increased R&D, and the approval of new immunotoxin therapies....
Yahoo Finance Community
01/10
Comment
funny news from Benzinga. I couldnt stop laughing. are they really trying to say granting options last month is the cause? really.. adding 200K shares is affecting the price. I mean, give me a break.Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are trading lower on Friday. The company announced the inducement stock option grants under Nasdaq Listing RuleWhat To Know: On Dec. 19 2024, Iovance approved options for 203,980 shares of its common stock to 48 new non-executive employees, granted at an exercise price of $7.22, equivalent to the stock’s closing price on the date of the grant....
Votes:
4
0
Yahoo Finance Community
01/10
Comment
I was not expecting to drop this fast closer to $5. For us long it’s pain but again sometimes investment comes with pain. What is your tolerance level? Can you hold when it goes down? Remember, so long you don’t sell your shares you didn’t lose anything. This will go up back to double digits by December....
Votes:
3
0
Yahoo Finance Community
01/10
Comment
While it is extremely painful to see it drop like this, this company has a first in class FDA approved drug- with no good competition in advanced stages of development- in a large unmet need population. The treatment is increasing in acceptance and melanoma experts are very thrilled with this treatment- based on personal communication. Multiple additional trial readouts are pending this year. Just with the approved indication, they project 500 million revenue for the 1st year. I do not have any concern for the long term....
Votes:
6
0
Yahoo Finance Community
01/10
Comment
IOVA has a manufacturing deal with WuXi.1-6-2025: Altaris will buy WuXi advanced therapies unit, I think UK & USA units. This deal is in response to US sanctions law. Doesn't appear to include WuXi Chinese located entities.I don't know a wholde lot about this. Anybody know what is manufactured in China and if this is the reason for the sell off?...
Yahoo Finance Community
01/10
Comment
Guy saying below that they have cash until mid2026... company says until 'early 2026' so in other words, about a years worth of cash; pretty normal for a biotech to raise again when they have only a years worth of cash left. Immediately after they announce a cash raise could be a very lucrative entry point......
Yahoo Finance Community
01/10
Comment
Back in early 2020 this company was valued at $3B. At a time where they were spinning wheels with the FDA and had no clear path to approval. Amongst others Cathy Wood was a believer and held this in her ARKK ETF. Several other companies were attempting to commercialize TIL therapy. Today, they’re going to generate about half a billion dollars in revenue in 2025, with many other potential catalysts on the horizon. And the direct competition is limited to one early stage company - Obsidian. I know the CEO from Obsidian. He’s a highly regarded oncologist. Nevertheless, IOVA is valued less than $2B today. Simply unexplainable....
Votes:
9
1
Quantexa News
01/10
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low – Here’s Why
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s share price reached a new 52-week low during trading on Wednesday . The company traded as low as $7.05 and last traded at $7.05, with a...
Yahoo Finance Community
01/13
Comment
company has only hinted to and released good things. company is firing on all cylinders on the next gen cell therapy. company has positive indications in a plethora of other cancers, should be cash flow positive this year and profitable within 2 along with approval for nsclc. there is a buyout coming without a doubt. continue to add and enjoy the ride....
Votes:
1
0
Yahoo Finance Community
01/13
Comment
How y'all think the 40+ new employees feel?? Why would iova of hired anyone, made any effort to get sec approval for stock compensation?? Why would employees agree to stock compensation, IF there were underlying issues or even the possibility??a lot of questions??...
Votes:
8
0
Quantexa News
01/14
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low – Here's Why
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) hit a new 52-week low on Tuesday . The stock traded as low as $5.77 and last traded at $5.78, with a volume of 16742751 shares. The stoc...
Quantexa News
01/14
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low - Here's Why
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) hit a new 52-week low on Tuesday . The stock traded as low as $5.77 and last traded at $5.78, with a volume of 16742751 shares. The stock...
Yahoo Finance Community
01/15
Comment
On Monday I emailed investor relations and no response back. That’s easily the fourth time I have emailed them with no response. Many companies are great at responding to their investors even if they cannot share much information. I’m not happy about that. They need to find a way to combat Hedge funds shorting this....
Votes:
1
1
Yahoo Finance Community
01/15
Comment
Great opportunity here . Unless the company reports revenues below estimates, the pps could double in the next 2 months. That's without Europe approval and positive news regarding the therapy for small cell lung cancer. I just bought 10 calls of the 1/16/2026 10 strike . May buy another 10-20 . I know it's risky but I figure in 12 months if it all goes according to plan.....the pps will be at least 18+...
Votes:
9
0
Yahoo Finance Community
01/15
Comment
I have 2 interests in this company. First, as an investor over the past 2 years and second as a potential patient. I have malignant, metastatic melanoma for the 3 years which is currently in remission thanks to KeyTruda.Earlier today I stated that this company needs a shake up. Joe, of course, was the first to run on the field in his tight little skirt waving pom-poms all over the place with his snarky comment. Well. to Joe and all the other cheerleaders, listen up, you might learn something.Having an "interim CEO" for such a long period of time is a red flag to many potential investors. It means that the BOD thinks Vogt is not qualified to run the company long term. Of course not, he's a General Counsel. In my 50+ years in business I can tell you that GCs almost always make terrible CEOs. And the fact …...
Votes:
16
3
Quantexa News
01/16
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 1-Year Low – What’s Next?
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $5.77 and last traded at $5.78, with...
Quantexa News
01/16
Sanders Morris Harris LLC Has $76,000 Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Sanders Morris Harris LLC cut its position in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 36.7% in the fourth quarter, according to its most recent 13F filing with the Sec...
Yahoo Finance Community
01/17
Comment
Its never going to get better for you longs, only worse. We are going to see $3. This has the potential to go the way of GMDA, another exotic drug that makes no money and was divested. You need to prepare you have a real possibility to lose your entire investment. You got that?...
Yahoo Finance Community
01/17
Comment
You think you are depressed now, wait until you see the 3s. I’ve seen this before just another approved biotech drug that makes no money and is eventually auctioned off. You need to come to grips that your investment might be obliterated forever. You let your family down holding on too long....
Votes:
3
7
Quantexa News
01/17
Iovance Biotherapeutics Inc (NASDAQ: IOVA): Can A Stock Be Down -19.86% YTD, And Still Be A Loser
Iovance Biotherapeutics Inc (NASDAQ:IOVA)'s traded shares stood at 1.43 million during the latest session, with the company's beta value hitting 0.56. At the last check today, the stock's price was $5...
Yahoo Finance Community
01/17
Comment
Wow... I bailed on this a few months ago. Thought I'd check in.Just. . . wow. The turd-factor has been even worse than I expected.Thought it would at least hold 7 bucks. Very sad, considering what they do.Something's obviously very wrong here. Congrats to anyone who sold at 18,and I don't even know what to say to those who got in at 3. Very sad, all-in-all.My condolences, longs. I (too) bled for this one....
Votes:
1
7
Yahoo Finance Community
01/17
Comment
This management team chose to dilute shareholders on the brink of approval. They had no immediate need for cash. They chose to dilute at what shareholders would consider a suppressed valuation, especially when on the brink of approval. I work in the industry. I can assure you they knew approval was coming. At the tail end of approval, you’re constantly interacting with the FDA on final correspondences. They knew they were days within approval. And then, after it rocketed up to $18 they chose not to dilute. These actions themselves, amongst others such as incompetent fiscal management all together, should have resulted in immediate termination of the entire management team. I welcome my fellow members to challenge my rational....
Votes:
1
0
Yahoo Finance Community
01/17
Comment
One share of the IOVA does not even come close to buying a Big Mac meal at McDonalds. Just awful. You greedy longs got what you deserved. You know who else is getting what they deserve? Your wife. She is at the Best Western with a real man, not some penny stock chaser. You can find her car in the parking lot, its next to the extended cab F-250. Yeah!...
Yahoo Finance Community
01/17
Comment
FYSA, Yahoo has now made it possible to unmute the previously muted. I took advantage to take a gander at the content from the “this user is muted” crowd. Upon review, I was quickly reminded of why I muted these posters in the first place. What a toxic wasteland. Their comments consist mainly of taunts, inanities, ad hominems, or outright lies. What I don’t read is a cogent argument for why IOVA is a bad investment. What is their bear thesis for IOVA? That they don’t have a permanent CEO? Laughable. Everyone knows why they don’t. Incompetent management? You mean the team who pioneered TIL therapy to the market? Upcoming competition? Who? Obsidian, which is years away and does not have the manufacturing infrastructure? Dilution? Okay; and I have even been critical of their sneaky use of the ATM, but we are likely just one more round from being CFP …...
Votes:
5
0
Yahoo Finance Community
01/17
Comment
I just saw what wh ph reference of executives selling shares, well ,to me, 1st they sold a portion of compensation, probably to cover taxes, 2nd if they waited till good news is released it would certainly qualify as insider trading, and only Nancy Pelosi gets away with that!!...
Votes:
2
0
Polygon News
01/17
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, a biotechnology company, announced the grant of inducement stock options to 41 new, non-executive employees. The stock options have an exercise price of $5.76 and vest over a...
Quantexa News
01/17
Iovance Biotherapeutics Announces New Stock Options for Employees
Author Ryan Hughes Updated : 01-17-2025 05:15 PM Iovance Biotherapeutics' New Stock Options for Employees Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), based in California, is continuously breaking...
Quantexa News
01/18
Hennion & Walsh Asset Management Inc. Has $2.49 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
NASDAQ:IOVA – Free Report ) by 4.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 335,981...
Yahoo Finance Community
01/18
Comment
You longs think you are so smart. Hey look how smart I am, I found a biotech on a message board. No, no you have been on a ruinous rampage, down 70% in a year on the IOVA. 70% down when the S&P has been up huge. No sir, you have failed yourself and your family. You are a financial washout....
Votes:
1
2
Quantexa News
01/19
Assenagon Asset Management S.A. Takes $12.93 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Assenagon Asset Management S.A. bought a new stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought...
Yahoo Finance Community
01/19
Comment
Hey omar! haven't heard from you in a while. I'm super mad you didn't pick me up from lax as we agreed upon. I hope your yeast infection is doing better. I'm flying out there again on Tuesday to baptize an OF girl. I'm landing at 3:15. can you pick me up then? also please pick me up some pigeon shwarma with extra skin. Thanks!...
Votes:
1
1
Yahoo Finance Community
01/19
Comment
Clean house of your Inv Bankers. Company has hit the mark consistently this past year. Yet bankers are failing them. Get new bankers that won’t feed and then bail out the shorts. You need bankers that will actually support the stock with good strong long term holders....
Votes:
4
1
Quantexa News
01/20
Is Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelman's Long-Term Stock Picks?
We recently published a list of Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks . In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands aga...
Quantexa News
01/20
Is Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
We recently published a list of Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands agai...
Quantexa News
01/21
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 1-Year Low – Should You Sell?
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as $5.57 and last traded at $5.73, with a volume...
Yahoo Finance Community
01/22
Comment
This is clearly psychological warfare against retail a there are not many available shares and shorts are pushing the company to dilute at a very low price - this is the game of bankers and tutes - they go long just in case but they make money by shorting and selling shares!...
Votes:
3
0
Yahoo Finance Community
01/22
Comment
Fellow longs just ask yourself…If Wayne had even the slightest bit of confidence in this management and their ability to deliver, why would he not take action and buy back some of the float? Why would he let his prized possession continue to crash to zero?...
Yahoo Finance Community
01/22
Comment
Also, all the bashing I get for being critical of management. I speak with senior level employees of this company and I get reassurance that leadership is non existent within the company’s fiber. It’s a mess. I remain a shareholder because I still believe in the product and therapy. Management is an absolute disgrace. They have to go. Go do some diligence yourself before you keep speaking about how great management is. They need to go. They are the overhang on the stock....
Votes:
1
4
Yahoo Finance Community
01/22
Comment
My fellow longs I was once as naive as you all are. I couldn’t see past the enormous potential of this game changing therapy. I knew management was a mess as I continue to reiterate this point. I kept accumulating shares. I’m a massive bag holder as we speak. It’s painful. But please wake up and smell the coffee. Something is not right. Ask yourself why this continues to be decimated even after all the great news. Why?...
Yahoo Finance Community
01/22
Comment
I haven’t posted in several months, have owned this for five years. Management is unable or unwilling to effectively counter the shorting . They are not Street savvy, they’re scientists. I would think that Wayne would have exercised his clout by now. It seems like they are just patiently waiting for continuing good results, handing out stock grants and think that everyone should be happy. They won’t be able to attract employees if the stock trades like garbage. These next couple of quarters really need to show something positive to generate enough momentum to burn the shorts, otherwise we are in for a long year ....
Votes:
6
0
Quantexa News
01/23
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Bought by Clear Harbor Asset Management LLC
Clear Harbor Asset Management LLC boosted its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 34.2% in the fourth quarter, according to its most recent filing with t...
Yahoo Finance Community
01/23
Comment
How does it feel to be a complete financial washout? While you have been decaying here with a failed IOVA investment, the rest of us are making money in a historic bull market. Just admit facts, you got played. Played by message board charlatans. I mean, you are like a simple fish in a lake, you saw a lore and got reeled in and filleted. It has to be humiliating. A real man takes care of his family financially, and you simply do not have the skillset to do so. It's why your wife makes the weekly visits to the Clarion Inn. See, you are not a man. You got nothing to offer, except the misery that follows. I think you are a failure....
Votes:
5
0
Yahoo Finance Community
01/23
Comment
When a company announces a buyout, the stock price of the target company (the company being bought) usually jumps significantly, as the acquiring company typically offers a premium price per share, which is higher than the current market value, enticing shareholders to sell their shares at a profit; this often leads to a quick increase in the stock price upon the announcement....
Votes:
1
1
Quantexa News
01/24
XML Financial LLC Buys 8,500 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
XML Financial LLC increased its position in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 58.6% during the 4th quarter, according to its most recent filing with the Securiti...
Yahoo Finance Community
01/24
Comment
The Independent Director Wayne made the biggest insider purchase in the last 12 months. That single transaction was for US$46m worth of shares at a price of US$9.15 each. That means that an insider was happy to buy shares at above the current price. It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels....
Votes:
3
0
Quantexa News
01/24
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Down -1.70%: Here's What Analysts' Predictions Are Now.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares, rose in value, with the stock price down by -1.70% to the previous day's close as strong demand from buyers drove the stock to $6.09. Actively observ...
Quantexa News
01/25
Arkadios Wealth Advisors Invests $150,000 in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Arkadios Wealth Advisors bought a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Ex...
Quantexa News
01/27
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have been given an average rating of "Moderate Buy" by the eight analysts that are covering the stock, Marketbeat reports. One e...
Polygon News
01/27
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts
Iovance Biotherapeutics, a biotech company, has seen its stock price drop significantly from its peak in 2021 despite the successful launch of its first therapy, Amtagvi, for advanced-stage melanoma....
Yahoo Finance Community
01/27
Comment
Shares of Iovance got ahead of themselves during the pandemic, but now they look severely underappreciated. The average sell-side analyst who follows the stock thinks it's worth $23.77 per share. That consensus target implies a gain of about 280% from recent prices....
Votes:
5
0
Yahoo Finance Community
01/27
Comment
Stifel reports Cornell Doc says they are treating 3 patients a month and in 6 months capacity for 6 month. Payer improvement. Manufacturing turn around down to 4 weeks from 6-8 weeks. Patients like not being on meds after treatment. If healthy enough, will opt for TIl over Replimmune. Sees little patient overlap. Replimmune good option if TIL fails....
Votes:
11
0
Yahoo Finance Community
01/27
Comment
Proleukin sales seem to be wild card on 2025 guidance. Stifel sees tough 1H and picking up in 2H. IOVA maintained last week 1H more likely flat not down. Stifel seems to think stock weakness due to skepticism that 2025 guide will be met. Due to stocking of new distributors this was expected to come down a bit. Flat is really positive....
Votes:
2
0
Yahoo Finance Community
01/29
Comment
In my opinion,Iovance has some of the smartest,experienced executives and board members in the cell therapy industry.I would think that they have laid out a five year plan to boost production and earn a significant profit.I think they are more valuable than the Car-t companies because of the market size for solid tumors and less competition....
Votes:
7
0
Yahoo Finance Community
01/29
Comment
EMA application is submitted on June 28, 2024."If the MAA for lifileucel is validated, which is anticipated in the third quarter of 2024, the Committee for Medicinal Products for Human Use (CHMP) is expected to issue a scientific opinion for the European Commission to adopt in 2025".Wonder when we can expect an update from the management on where we stand with the EMA process....
Votes:
1
0
Yahoo Finance Community
01/29
Comment
Nobody knows what February 26 will do. It is my opinion that this is a push down for yet much higher gains. It's not expected to skyrocket right now but, move up with added revenues,approvals and patients. If you have big $$ and can drive it down to ensure a good profit.. It simply makes sense....
Votes:
1
0
Yahoo Finance Community
01/29
Comment
Everyone read the piece "Where will IOVA be in 5 years? " and you'll understand a lot more about why it's 6 dollars now and may hover between 5 and 10 dollars over the next year or more. This is a long term play and investment and if you believe they will succeed you will all be better off to stop criticizing , relax and use your own date based on analysis from people who know to start either praising or criticizing this company . If you are frustrated and angry and can't wait you are better off getting out ....
Votes:
5
2
Yahoo Finance Community
01/29
Comment
Chances of growth here will be based on EPS growth realized. According to consensus analysts estimate, IOVA isn't supposed to turn the corner to cash flow positive until sometime in 2027(market only looks out as a discounting mechanism six months nowadays so this is going to be nothing more than choppy waters until then), and even then there afterwards, there isn't any analysts estimating growth much past $1 EPS looking out for about the next five years after 2027....Where are analysts getting it all wrong here?...
Yahoo Finance Community
01/29
Comment
Everybody talking about this company being a long term play. It’s down 70% over the past five years. Endless dilutions over that period. Acts and operates as if it isn’t a public company. Zero regard or care for building shareholder value. Management a bunch of scientists that have no clue how to run a company. It’s actually comical that people believe in this management. Pathetic....
Votes:
3
10
Quantexa News
01/30
Analysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Price Target at $23.00
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the company, MarketBeat Ra...
Yahoo Finance Community
01/30
Comment
Management’s focus on execution and meeting their (unheard of) >1 year profit guidance is more important to me (and likely the institutional investors) than early or hyped research updates (that would probably cause more stock price volatility anyway). I am not sure that management could do anything more, except maybe borrow money (if needed, since they can write off the interest once cash flow positive) instead of doing another ATM....
Votes:
2
0
Yahoo Finance Community
01/31
Comment
Piper probably sold a bunch of $6 calls for this week and needed bring it down because again they called 6 ATC's which said they are at a steady flow of infusions so there hasn't been any slow down. The thing they missed the first time was Proleukin sales and it sounds like they forgot about that again....
Votes:
2
1
Yahoo Finance Community
01/31
Comment
Unfortunately, you won’t find another public company with incredible life altering technology but managed by pure incompetence. Wall Street has spoken my friends. A product is essentially worthless without the proper support. Until management is purged this goes no where....
Yahoo Finance Community
01/31
Comment
More bashers is a good sign. People don't go on boards and bash just out of boredom.Volume has been very good. Price action just up and down doesn't concern me and my 20k shares. Some more calls taken out today. March is calls are building. Management is fine that talk is nonsense. THey will be updating us soon, until then buy or ignore. Go Eagles !!!...
Votes:
2
2
Yahoo Finance Community
01/31
Comment
Revenue Guidance in FY25: Total product revenue remains on track to be within the range of $450 to $475 million in 2025, the first full calendar year of Amtagvi sales. Gross margins are increasing as the launch advances and are expected to surpass 70% over the next several years. In line with anticipated growth in Amtagvi demand, Proleukin revenue is also expected to increase significantly in 2025 and beyond....
Votes:
2
0
Yahoo Finance Community
01/31
Comment
I sold for a $15k haircut. Made the money back on IBRX which is also a huge risk given their cash position, but ultimately decided the ibrx ceiling was higher inasmuch as they don't require cell harvesting (although this protects you against generics). I see this as a 2 bagger but ibrx as a 6 or 7 bagger. glta!...
Yahoo Finance Community
02/01
Comment
Adding when things get hard but the original thesis for my buy still remains intact has led to some of my best gains. I can’t guarantee that’s the case here, but when I step back and look I’m compelled to continue to DCA as much as my meager portfolio will allow...
Votes:
4
0
Yahoo Finance Community
02/01
Comment
This is why I bought at 6 range. Biotechs trade at 4-5x on sales. So they can do 450m in 2025 implying a 1.8 to 2.25B valuation. They have an opportunity in the EU and a strong pipeline. In a buyout situation it’s typically 9-10x potential sales, implying a 4 - 4.5B valuation, plus pipeline potential....
Votes:
4
1
Yahoo Finance Community
02/03
Comment
We’re going to open at a new 52 week low. Well done, management! You’re executing flawlessly. Not a single update from your last earnings call. Endless dilutions. Likely fully tapped the ATM. Missed your goal EU target and have given no latest estimate update. Well done!...
Votes:
1
1
Quantexa News
02/03
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 52-Week Low Following Analyst Downgrade
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report )'s stock price hit a new 52-week low during trading on Monday after Piper Sandler lowered their price target on the stock from $10.00 to...
Yahoo Finance Community
02/03
Comment
We have 2 guys here that are supper annoying here , they are both long. One is always whining , other none stop pumping with his none sense . N yes I m long as well. Been slowly adding. But man these two guys drive me nut. I find Peter more entertaining than these two. Pretty sure u all know whose I m referring to !!...
Votes:
3
1
Quantexa News
02/04
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low Following Analyst Downgrade
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) hit a new 52-week low on Monday after Piper Sandler lowered their price target on the stock from $10.00 to $7.50. Piper Sandler...
Quantexa News
02/04
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low Following Analyst Downgrade
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) hit a new 52-week low on Monday after Piper Sandler lowered their price target on the stock from $10.00 to $7.50. Piper Sandle...
Yahoo Finance Community
02/05
Comment
Potential competitor Turnstone discontinued TIL program due to funding mfg costs. First mover IOVA managed through this hurdle and now driving to profitability. Funding appears difficult for second fiddle. We will lap the field. Please go it alone....
Votes:
12
0
Yahoo Finance Community
02/05
Comment
Longs be careful here, hopefully we start to climb, but could be our not so friendly MM letting it run a bit, have retail buy weekly calls at $6 n then take all your premium by the end of the week. Don’t fall for that trap. Keep on accumulating stock and LEAPS, and imo, you will see a $30, or more, stock price within a year or two. Just how I see it!!!!...
Votes:
3
0
Yahoo Finance Community
02/07
Comment
I have 5000 shares at 6.30. I am holding, but this almost feels like GMDA. Good drug, good technology, but just too expensive, too complex and terrible margins. I'll ride this into the ground if I have to, but this bio business is about recurring treatments, not one time hits. Pretty sure I will be fleeced....
Votes:
1
1
Yahoo Finance Community
02/07
Comment
$223 billion spent on oncology research in 2023. By 2028 this is expected to increase to $409 billion. The top 10 companies produced oncology revenue combined of $$129.7 billion in 2024. Think of the waste vs proven, new and approved TIL therapy from first mover Iovance. We are way past the waste/funding a hope and dream stage. Smart money will follow...
Votes:
7
0
Yahoo Finance Community
02/07
Comment
Who was that insider that bought all those shares in the 9s? I feel like a clown buying at 6.30. He might be ready check himself into an asylum or something. What a disaster this thing has been. I can see the CEO laughing saying you are all paying my salary....
Yahoo Finance Community
02/08
Comment
I am holding only because I was patient on TGTX when I rode it from 11 to 7, then sold at 22. Now, I sold too early but you get the point. I believe in this company's technology in the medical space, and I have an MBA so I know what I am talking about. But these losses are distressing. I am already down $4,000 and its not even been 10 days since my purchase. I don't appreciate why management is allowing this to happen. But staying long. I have 5000 shares so basically a whale....
Votes:
1
0
Yahoo Finance Community
02/09
Comment
I am hopeful this becomes like TGTX, beaten down and than a quick ascension up. I feel a little ridiculous buying in a 6.30, its been nothing but losses the day I bought. Certainly not what I was promised. Having an MBA usually gives me a significant advantage, we'll see if that edge continues to pay off....
Votes:
2
0
Yahoo Finance Community
02/09
Comment
Mark, if you are lying to us, I am going to open up a can all over your face. You will be insta-reported to YMB management! Never disrespect an MBA(Ivy league at that). We shall see. Hopefully you are not making things up. You got that? Do you?...
Votes:
3
0
Yahoo Finance News
02/10
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer Iovance Biotherapeutics, Inc. Mon, Feb 10, 2025, 7:00 AM 8 min read In This Article: IOVA -0.47% Iovance Biotherapeutics, Inc. SA...
Quantexa News
02/10
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
SAN CARLOS, Calif. , Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclon...
Quantexa News
02/10
Iovance Biotherapeutics (IOVA) Appoints Dan Kirby as Chief Commercial Officer
February 10, 2025 7:00 AM EST Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating l...
Quantexa News
02/10
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...
Quantexa News
02/10
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...
Quantexa News
02/10
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
Iovance Biotherapeutics, Inc. SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing,...
Quantexa News
02/10
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
Iovance Biotherapeutics, Inc. announced that Dan Kirby will join the Company?s executive leadership team in the newly created role of Chief Commercial Officer, effective 10 February 2025. Prior to joi...
Quantexa News
02/10
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...
Quantexa News
02/11
Shaker Investments LLC OH Has $430,000 Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Shaker Investments LLC OH trimmed its stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 42.3% during the fourth quarter, according to its most recent disclosure with the Securiti...
Quantexa News
02/11
Shaker Investments LLC OH Has $430,000 Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Shaker Investments LLC OH trimmed its position in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 42.3% in the 4th quarter, according to the company in its most recent Form 13...
Quantexa News
02/11
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month Low - What's Next?
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) shares reached a new 52-week low on Monday . The stock traded as low as $5.50 and last traded at $5.50, with a volume of 3928988 shares tr...
Yahoo Finance Community
02/12
Comment
Pls stop with the squeeze dream!! Been hearing it like forever !! Who are we kidding ? The shorts are wining this battle by far !! We re drowning big time n no help so far. Just hope that we Long will win the war !! Also pls stop with this is a gift, if I knew that I would never tell a soul !!...
Votes:
3
0
Yahoo Finance Community
02/12
Comment
Stifel updated survey of 9 ATC’s. 31% increase in Amtagvi infusions. Out of spec drops to 17.9% vs 26.9%. 2 Doc’s think REPL will steal some patients. The other 7 feel no patient overlap. If patient healthy enough for Amtagvi, it is the better option. Payer authorization still clunky....
Votes:
13
0
Yahoo Finance Community
02/12
Comment
Important to remember that Amtagvi efficacy improves with duration. Seeing CR several years after infusion this is 1x treatment. Very cost efficient when you compare to 3.4,5, unsuccessful lines of treatment. Doc’s need to move patients to Amtagvi as soon as they know 1L isn’t going to work. Better tumor specimen healthier patient, better outcome much lower overall cost to system...
Votes:
12
0
Yahoo Finance News
02/12
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Iovance Biotherapeutics, Inc. Wed, Feb 12, 2025, 2:30 PM 7 min read In This Article: IOVA Iovance Biotherapeutics...
Quantexa News
02/12
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 1-Year Low – Here's Why
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $5.50 and last traded at $5.50, with a volume...
Quantexa News
02/12
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 52-Week Low – What's Next?
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) hit a new 52-week low during trading on Monday . The company traded as low as $5.50 and last traded at $5.50, with a volume of...
Quantexa News
02/14
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.3% – Still a Buy?
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report )'s share price traded up 7.3% on Friday . The company traded as high as $5.70 and last traded at $5.73. 2,133,652 shares changed hands du...
Quantexa News
02/15
Banque Pictet & Cie SA Acquires 54,832 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Banque Pictet & Cie SA raised its holdings in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 17.0% during the fourth quarter, according to its most recent filing with the Sec...
Quantexa News
02/15
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.3% - Still a Buy?
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report)'s share price traded up 7.3% on Friday . The company traded as high as $5.70 and last traded at $5.73. 2,133,652 shares changed hands duri...
Quantexa News
02/16
Choreo LLC Has $218,000 Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Choreo LLC lifted its stake in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 39.5% during the fourth quarter, Holdings Channel reports. The fund owned 30,445 shares of the b...
Quantexa News
02/16
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired by Bank Pictet & Cie Europe AG
Bank Pictet & Cie Europe AG increased its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 10.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC....
Quantexa News
02/16
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 7.3% Higher – Here's What Happened
Iovance Biotherapeutics, Inc. ( – ) shares shot up 7.3% on Friday . The company traded as high as $5.70 and last traded at $5.73. 2,133,652 shares were traded during mid-day trading, a decline of 75%...
Quantexa News
02/16
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.3% – Time to Buy?
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report )'s stock price traded up 7.3% during trading on Friday . The stock traded as high as $5.70 and last traded at $5.73. 2,133,652 shares cha...
Quantexa News
02/18
Rice Hall James & Associates LLC Reduces Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Rice Hall James & Associates LLC trimmed its holdings in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 5.0% during the 4th quarter, according to the company in its most rece...
Quantexa News
02/18
Rice Hall James & Associates LLC Lowers Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Rice Hall James & Associates LLC trimmed its stake in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 5.0% in the 4th quarter, according to its most recent 13F filing with the...
Quantexa News
02/18
Recent developments with Iovance Biotherapeutics Inc (IOVA) have led to the company's beta value being reach 0.89 cents.
On Friday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) was 4.31% up from the session before settling in for the closing price of $5.34. A 52-week range for IOVA has been $5.05 – $18.33. Here's Your FR...
Yahoo Finance Community
02/18
Comment
LJ disappears for months and reappears to bash leading in to Q Revenue and business update report. Set my watch on his timing of posts. No question trading small bio can be rewarding. Can also be punishment. But almost always miss really big gains. Know your stock and game. LJ’s thoughts have had no relevance to me for 18 months....
Votes:
2
1
Quantexa News
02/18
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financi
SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Quantexa News
02/18
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Quantexa News
02/18
Iovance Biotherapeutics To Report Fourth Quarter And Full Year 2024 Financial Results And Corporate Updates On February 27, 2025
MENAFN - GlobeNewsWire - Nasdaq) SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and deli...
Yahoo Finance Community
02/19
Comment
I believe big pharma is very interested in technology. But, not so interested in building out the infrastructure. Outside of their core competency. So iova is building out the platform and will have optionality to go alone or sell turnkey operation with deep pipeline. If so, this should maximize shareholder value....
Votes:
4
1
Yahoo Finance Community
02/19
Comment
I can't exactly see what the muted user was saying about ATM but if the company comes out and says they used it that would mean we would be set till profitability. If they haven't used it yet it leaves the door open for shorts to use it as an excuse for future dilution. I hope management took that opportunity away from them....
Votes:
2
0
Yahoo Finance Community
02/19
Comment
TIL’n ain’t easy. TIL therapy has been a proven treatment since 1988. The challenge has always been commercializing it, as both LYEL and TSBX recently discovered. To date, only IOVA has been able to successfully bring TILs to market. That was accomplished through significant cash burn and dilution, which bears on this board have noted. It’s simple: if you consider that irresponsible financial practice, sell; if you consider that sound investment, buy. Your denarii, your decision. I am in the latter camp and added more today. Why? The same reason tutes have increased their ownership of IOVA to 91% overall. The science. My favorite data point is IOV-COM-202: 64.3% ORR w/EGRFwt and 54.5% ORR w/EGRFwt PD-L1 negative, w/DoR not reached at nearly 2 years. Second is the Stifel report, which notes that for patients “an important advantage of being treated with Amtagvi is they are able to enjoy drug-free periods, …...
Votes:
27
0
Yahoo Finance News
02/20
Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know Zacks Equity Research T...
Yahoo Finance Community
02/20
Comment
IOVA management has not, in any way shape or form, provided guidance as to when they expect to break even or become profitable. They’re running the business as if it’s a never ending ATM. Perhaps that’s one of the reasons why the short interest is relentless....
Votes:
6
0
Yahoo Finance Community
02/20
Comment
For the management bashers can you please provide a company where management did everything you wanted? would like the example to be a commercial stage biotech company so it can be an apples to apples comparison. Do you only look at what they are doing wrong vs what they have done right?...
Votes:
7
2
Quantexa News
02/21
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of “Moderate Buy” by Analysts
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Mar...
Quantexa News
02/21
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the stock, Mar...
Quantexa News
02/21
Hussman Strategic Advisors Inc. Sells 63,000 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Hussman Strategic Advisors Inc. cut its holdings in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 42.9% during the 4th quarter, according to its most recent 13F filing with the Securi...
Yahoo Finance Community
02/21
Comment
there was a nice build up with last earnings. The better then expected report. Since then the stock has lost 50%.Now with earnings next week there has been no movement. Maybe this is the time the stock rises after report. Nothing has made sense for 2 years....
Votes:
5
0
Quantexa News
02/21
Market Recap: Iovance Biotherapeutics Inc (IOVA)'s Negative Momentum, Closing at 5.61
For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth. The closing price of Io...
Yahoo Finance Community
02/21
Comment
I get being unsatisfied by management updates. But I’ve seen way too many times where companies of this size get sued because of the way they shared updates and information. As long as they don’t hide material info, I’m ok with a little ambiguity. And don’t mind waiting until results are official to hear them. If you believe in the long term prognosis it shouldn’t matter if the share price raises next week or next year....
Votes:
11
0
Yahoo Finance Community
02/21
Comment
All the games and manipulation of IOVA are about to come to an end if the quarterly report beats guidance (which I expected will do).No other stock offers a one-step solution that can reliably cure advanced cancer. A short squeeze is possible following the earnings announcement. There is a strong potential for new all-time highs in the not too distant future; and, I would look for a near term potential price in the range of $14 as a likely outcome of iova meeting or beating its guidance. This stock has great potential beyond melanoma, and is ridiculously undervalued in my opinion. Please do your own DD and research and I think you will agree. The risk/reward potentials here are very favorable,IMO....
Votes:
19
0
Quantexa News
02/21
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 6.9% – Here's Why
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) shares shot up 6.9% during trading on Friday . The company traded as high as $6.03 and last traded at $6.00. 3,881,533 shares were traded...
Quantexa News
02/21
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.9% – Still a Buy?
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) rose 6.9% on Friday . The stock traded as high as $6.03 and last traded at $6.00. Approximately 3,881,533 shares traded hands during mid-d...
Yahoo Finance News
02/21
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Iovance Biotherapeutics, Inc....
Quantexa News
02/22
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 6.9% - Here's Why
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) shares shot up 6.9% during trading on Friday . The company traded as high as $6.03 and last traded at $6.00. 3,881,533 shares were traded...
Quantexa News
02/23
Principal Financial Group Inc. Reduces Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Principal Financial Group Inc. trimmed its stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 9.6% in the 4th quarter, according to the company in its most recent 13F filing with...
Quantexa News
02/23
Principal Financial Group Inc. Sells 386,397 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Principal Financial Group Inc. cut its stake in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 9.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 3,646,787 shares...
Quantexa News
02/23
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.9% – Time to Buy?
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) rose 6.9% during trading on Friday . The stock traded as high as $6.03 and last traded at $6.00. Approximately 3,881,533 shares changed...
Quantexa News
02/23
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
Iovance Biotherapeutics, Inc. SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delive...
Quantexa News
02/24
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $21.07 Average Price Target from Brokerages
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) have earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat.com...
Quantexa News
02/24
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $21.07 Consensus Price Target from Brokerages
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) has been given an average rating of "Moderate Buy" by the seven ratings firms that are currently covering the company, Marketbeat Ratings...
Quantexa News
02/24
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $21.07 Consensus Price Target from Brokerages
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) has been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the company, Marketbeat Ratings...
Reddit
02/24
Analysis of Iovance Biotherapeutics ($IOVA): potential big jump from $5.8
Hi everyone, I currently have an **open position of $18,000** in **Iovance Biotherapeutics ($IOVA)**. While I don’t have a medical background, I conducted thorough due diligence on the company and us...
Reddit
02/24
Analysis of Iovance Biotherapeutics ($IOVA): potential big jump from $5.8
Hi everyone, I currently have an **open position of $18,000** in **Iovance Biotherapeutics ($IOVA)**. While I don’t have a medical background, I conducted thorough due diligence on the company and us...
Quantexa News
02/25
Iovance Biotherapeutics Inc (IOVA) 20 Days SMA touches -3.23%: The odds favor the bear
On Tuesday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) opened lower -3.98% from the last session, before settling in for the closing price of $5.78. Price fluctuations for IOVA have ranged from $5.05...
Quantexa News
02/25
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Could Make Significant Gains?
In the latest trading session, 2.02 million Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares changed hands as the company's beta touched 0.89. With the company's most recent per share price at $5.26 c...
Quantexa News
02/26
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of “Moderate Buy” by Brokerages
NASDAQ:IOVA – Get Free Report ) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One investment ana...
Quantexa News
02/26
Brokerages Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Target Price at $21.07
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) has been assigned a consensus rating of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat.com repor...
Yahoo Finance News
02/27
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024 Iovanc...
Quantexa News
02/27
IOVANCE BIOTHERAPEUTICS, INC. Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
February 27, 2025 at 04:01 pm EST Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range o...
Quantexa News
02/27
IOVANCE BIOTHERAPEUTICS, INC. Earnings Flash (IOVA) Iovance Biotherapeutics Reports Q4 Revenue $73.7M, vs. FactSet Est of $72.1M
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its...
Quantexa News
02/27
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
Iovance Biotherapeutics, Inc. Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $1...
Quantexa News
02/27
IOVANCE BIOTHERAPEUTICS, INC. Iovance Biotherapeutics: Q4 Earnings Snapshot
February 27, 2025 at 04:30 pm EST SAN CARLOS, Calif. (AP) — SAN CARLOS, Calif. (AP) — Iovance Biotherapeutics Inc. (IOVA) on Thursday reported a loss of $78.6 million in its fourth quarter. On a per...
Yahoo Finance News
02/27
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates Zacks Equity Research Thu, Feb 27, 2025, 5:25...
Quantexa News
02/27
Iovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Int...
Yahoo Finance News
02/28
Iovance Biotherapeutics Inc (IOVA) Q4 2024 Earnings Call Highlights: Strong Revenue and ...
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Iovance Biotherapeutics Inc (IOVA) Q4 2024 Earnings Call Highlights: Strong Revenue and ... GuruFocus News Thu, Feb...
Quantexa News
02/28
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of “Moderate Buy” by Brokerages
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) has been given an average rating of “Moderate Buy” by the five brokerages that are covering the stock, Marketbeat reports. One analyst h...
Quantexa News
02/28
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $21.07 Average PT from Analysts
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) has been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the firm, MarketB...
Yahoo Finance News
02/28
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty Zacks Equity Research Fri, Feb 28, 2025, 9:44 AM 5...
Yahoo Finance News
02/28
Truist Adjusts Price Target on Iovance Biotherapeutics to $15 From $25, Maintains Buy Rating
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM Truist Adjusts Price Target on Iovance Biotherapeutics to $15 From $25, Maintains Buy Rating MT Newswires Fr...
Quantexa News
02/28
IOVA stock touches 52-week low at $3.92 amid market challenges
In a challenging market environment, shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) have reached a 52-week low, dipping to $3.92. According to InvestingPro data, the company maintains a stron...
Quantexa News
02/28
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low Following Analyst Downgrade
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report )'s stock price reached a new 52-week low on Friday after Robert W. Baird lowered their price target on the stock from $24.00 to $20.00. R...
Quantexa News
02/28
Stock Traders Buy High Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) saw unusually large options trading activity on Friday. Traders bought 20,884 call options on the stock. This represents an increase of...
Quantexa News
02/28
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty
Iovance Biotherapeutics, Inc. IOVA incurred a fourth-quarter 2024 loss of 26 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents. In the year-ago quarter, the company rep...
Quantexa News
02/28
After A Decline Of -354.84% From The High, Can Iovance Biotherapeutics Inc (NASDAQ: IOVA) Recover Quickly?
Iovance Biotherapeutics Inc (NASDAQ:IOVA)'s traded shares stood at 25.95 million during the latest session, with the company's beta value hitting 0.90. At the last check today, the stock's price was $...
Quantexa News
03/01
Traders Purchase Large Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) was the recipient of some unusual options trading on Friday. Stock traders purchased 20,884 call options on the company. This is an increa...
Quantexa News
03/01
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low Following Analyst Downgrade
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) hit a new 52-week low during trading on Friday after Robert W. Baird lowered their price target on the stock from $24.00 to $20.00. Robe...
Yahoo Finance News
03/01
Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations editorial-team@simplywallst.com (Simply Wal...
Quantexa News
03/01
Stock Traders Buy High Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) saw unusually large options trading activity on Friday. Traders bought 20,884 call options on the stock. This represents an increase of ap...
Quantexa News
03/02
Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 12-Month Low After Analyst Downgrade
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) reached a new 52-week low during trading on Friday after Robert W. Baird lowered their price target on the stock from $24.00 to $20.00....
Quantexa News
03/03
Rhumbline Advisers Has $2.86 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Rhumbline Advisers boosted its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 9.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exc...
Quantexa News
03/03
Iovance Biotherapeutics Inc’s (IOVA) Stock: A Long-Term Performance Analysis
The stock of Iovance Biotherapeutics Inc (IOVA) has seen a -26.73% decrease in the past week, with a -30.23% drop in the past month, and a -54.31% decrease in the past quarter. The volatility ratio fo...
Yahoo Finance News
03/03
Chardan Cuts Price Target on Iovance Biotherapeutics to $30 From $34, Keeps Buy Rating
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM Chardan Cuts Price Target on Iovance Biotherapeutics to $30 From $34, Keeps Buy Rating MT Newswires Mon, Mar...
Quantexa News
03/03
Grandfield & Dodd LLC Increases Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Grandfield & Dodd LLC increased its holdings in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 85.3% in the fourth quarter, according to the company in its most recent disclosure with...
Quantexa News
03/04
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 5.8% After Analyst Downgrade
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s stock price traded down 5.8% during trading on Tuesday after Truist Financial lowered their price target on the stock from $25.00 to $15...
Quantexa News
03/05
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.8% After Analyst Downgrade
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) shares fell 5.8% on Tuesday after Truist Financial lowered their price target on the stock from $25.00 to $15.00. Truist Financial current...
Quantexa News
03/07
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 52-Week Low – Time to Sell?
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s stock price hit a new 52-week low during trading on Friday . The company traded as low as $3.58 and last traded at $3.61, with a volume...
Quantexa News
03/08
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 52-Week Low - Time to Sell?
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report)'s stock price hit a new 52-week low during trading on Friday . The company traded as low as $3.58 and last traded at $3.61, with a volume...
Quantexa News
03/09
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month Low – Here's Why
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) shares hit a new 52-week low during mid-day trading on Friday . The company traded as low as $3.58 and last traded at $3.61, with a volu...
Quantexa News
03/10
Navigating the Volatility of Iovance Biotherapeutics Inc’s (IOVA) Stock
The stock of Iovance Biotherapeutics Inc (IOVA) has gone down by -11.45% for the week, with a -38.52% drop in the past month and a -57.04% drop in the past quarter. The volatility ratio for the week i...
Quantexa News
03/12
Proficio Capital Partners LLC Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Proficio Capital Partners LLC acquired a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) in the fourth quarter, according to the company in its most recent disclosure...
Quantexa News
03/12
30,429 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Bought by Proficio Capital Partners LLC
Proficio Capital Partners LLC purchased a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) during the fourth quarter, HoldingsChannel reports. The fund purchased 30,429...
Yahoo Finance News
03/12
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up? David Jagielski, The Motley Fo...
Polygon News
03/12
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
Iovance Biotherapeutics stock has fallen nearly 80% from its high, raising the question of whether it is now a bargain buy. While the company has seen significant revenue growth and FDA approval for i...
Quantexa News
03/12
Quarterly Snapshot: Quick and Current Ratios for Iovance Biotherapeutics Inc (IOVA)
Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth. The closing price of Iovance Biotherapeutic...
Quantexa News
03/13
23,000 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Bought by Avantax Planning Partners Inc.
NASDAQ:IOVA – Free Report ) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 23,000 shares of the biotechnology company's stock,...
Quantexa News
03/13
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low – Time to Sell?
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) reached a new 52-week low on Thursday . The company traded as low as $3.58 and last traded at $3.61, with a volume of 4820141...
Quantexa News
03/13
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low – Time to Sell?
Shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Get Free Report ) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $3.58 and last traded at $3.61, with a v...
